



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

28 July 2022
EMA/CHMP/624461/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 20-23 June 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	8
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda	8
1.3.	Adoption of the minutes	8
2.	Oral Explanations	9
2.1.	Pre-authorisation procedure oral explanations.....	9
2.1.1.	Sunlenca - lenacapavir - EMEA/H/C/005638.....	9
2.1.2.	maribavir - Orphan - EMEA/H/C/005787	9
2.1.3.	fosdenopterin - Orphan - EMEA/H/C/005378	9
2.1.4.	Pepaxti - melphalan flufenamide - Orphan - EMEA/H/C/005681	10
2.2.	Re-examination procedure oral explanations	10
2.3.	Post-authorisation procedure oral explanations	10
2.4.	Referral procedure oral explanations	10
3.	Initial applications	10
3.1.	Initial applications; Opinions.....	10
3.1.1.	COVID-19 Vaccine (inactivated, adjuvanted) Valneva - COVID-19 vaccine (inactivated, adjuvanted, adsorbed) - EMEA/H/C/006019	10
3.1.2.	Sunlenca - lenacapavir - EMEA/H/C/005638.....	11
3.1.3.	Pepaxti - melphalan flufenamide - Orphan - EMEA/H/C/005681	11
3.1.4.	Ranivisio - ranibizumab - EMEA/H/C/005019.....	12
3.1.5.	Rayvow - lasmiditan - EMEA/H/C/005332	12
3.1.6.	Roctavian - valoctocogene roxaparvovec - PRIME - Orphan - ATMP - EMEA/H/C/005830 ..	13
3.1.7.	Scemblix - asciminib - Orphan - EMEA/H/C/005605	13
3.1.8.	Vegzelma - bevacizumab - EMEA/H/C/005534.....	14
3.1.9.	Vyvgart - efgartigimod alfa - Orphan - EMEA/H/C/005849	14
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	15
3.2.1.	doxorubicin hydrochloride - EMEA/H/C/005330	15
3.2.2.	dabigatran etexilate - EMEA/H/C/005639.....	15
3.2.3.	dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362	15
3.2.4.	sutimlimab - Orphan - EMEA/H/C/005776.....	16
3.2.5.	maralixibat - Orphan - EMEA/H/C/005857	16
3.2.6.	maribavir - Orphan - EMEA/H/C/005787	16
3.2.7.	tirzepatide - EMEA/H/C/005620	16
3.2.8.	fosdenopterin - Orphan - EMEA/H/C/005378	17
3.2.9.	iodine (131I) omburtamab - Orphan - EMEA/H/C/005499.....	17

3.2.10.	dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155	17
3.2.11.	teriflunomide - EMEA/H/C/005962	18
3.2.12.	teriparatide - EMEA/H/C/005793	18
3.2.13.	ranibizumab - EMEA/H/C/005617	18
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	18
3.3.1.	sodium phenylbutyrate / ursodolicolaurine - Orphan - EMEA/H/C/005901	18
3.3.2.	gadopiclenol - EMEA/H/C/005626	19
3.3.3.	dabigatran etexilate - EMEA/H/C/005922.....	19
3.3.4.	dapagliflozin - EMEA/H/C/006006	19
3.3.5.	pegunigalsidase alfa - Orphan - EMEA/H/C/005618.....	19
3.3.6.	daprodustat - EMEA/H/C/005746.....	20
3.3.7.	sitagliptin / metformin hydrochloride - EMEA/H/C/005778	20
3.3.8.	SARS-CoV-2 prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754	20
3.3.9.	filgrastim - EMEA/H/C/005888	20
3.4.	Update on on-going initial applications for Centralised procedure.....	21
3.4.1.	sirolimus - Orphan - EMEA/H/C/005896.....	21
3.4.2.	germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165.....	21
3.4.3.	octreotide - Orphan - EMEA/H/C/005826	21
3.4.4.	pemetrexed - EMEA/H/C/005848	21
3.4.5.	surufatinib - EMEA/H/C/005728.....	22
3.4.6.	sorafenib - EMEA/H/C/005921.....	22
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	22
3.5.1.	Tuznue - trastuzumab - EMEA/H/C/005066 / Hervalous - trastuzumab - EMEA/H/C/00588022	
3.6.	Initial applications in the decision-making phase.....	23
3.7.	Withdrawals of initial marketing authorisation application	23

4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	23
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	23
4.1.1.	Procysbi - mercaptamine - Orphan - EMEA/H/C/002465/X/0035.....	23
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	23
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	23
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	24
4.4.1.	Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G	24
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	24

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 24

5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....	24
5.1.1.	Buvidal - buprenorphine - EMEA/H/C/004651/II/0017	24
5.1.2.	Crysvita - burosumab - Orphan - EMEA/H/C/004275/II/0023	25
5.1.3.	Dupixent - dupilumab - EMEA/H/C/004390/II/0060	25
5.1.4.	Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0012	26
5.1.5.	Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0014	26
5.1.6.	Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0001.....	27
5.1.7.	Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G	27
5.1.8.	Imbruvica - ibrutinib - EMEA/H/C/003791/II/0070.....	28
5.1.9.	Imbruvica - ibrutinib - EMEA/H/C/003791/II/0073.....	28
5.1.10.	Kerendia - finerenone - EMEA/H/C/005200/II/0001/G	29
5.1.11.	Libtayo - cemiplimab - EMEA/H/C/004844/II/0026	29
5.1.12.	Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G	30
5.1.13.	Lynparza - olaparib - EMEA/H/C/003726/II/0051/G	30
5.1.14.	Nubeqa - darolutamide - EMEA/H/C/004790/II/0009	30
5.1.15.	Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0009	31
5.1.16.	Opdivo - nivolumab - EMEA/H/C/003985/II/0117	31
5.1.17.	Reblozyl - luspaterecept - Orphan - EMEA/H/C/004444/II/0009	32
5.1.18.	Rinvoq - upadacitinib - EMEA/H/C/004760/II/0016	32
5.1.19.	Spikevax - elasomeran - EMEA/H/C/005791/II/0067.....	33
5.1.20.	Ultomiris - ravulizumab - EMEA/H/C/004954/II/0026.....	33
5.1.21.	Xalkori - crizotinib - EMEA/H/C/002489/II/0072	34
5.1.22.	Xydalba - dalbavancin - EMEA/H/C/002840/II/0043.....	34
5.1.23.	Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0036.....	35
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	35
5.2.1.	Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G.....	35
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	35

6. Medical devices 36

6.1.	Ancillary medicinal substances - initial consultation	36
6.2.	Ancillary medicinal substances – post-consultation update.....	36
6.3.	Companion diagnostics - initial consultation	36
6.3.1.	in vitro diagnostic medical device - EMEA/H/D/006078.....	36

6.4.	Companion diagnostics – follow-up consultation	36
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	36
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use).....	36
8.	Pre-submission issues	36
8.1.	Pre-submission issue.....	36
8.2.	Priority Medicines (PRIME).....	37
8.2.1.	List of applications received	37
8.2.2.	Recommendation for PRIME eligibility.....	37
9.	Post-authorisation issues	37
9.1.	Post-authorisation issues	37
9.1.1.	Cuprior - trientine - EMEA/H/C/004005/R/0018	37
9.1.2.	Elzonris - tagraxofusp – Orphan - EMEA/H/C/005031/II/0009	37
9.1.3.	Episalvan – birch bark extract – EMEA/H/C/003938	38
9.1.4.	Cetrotide - cetorelix – EMEA/H/C/000233	38
9.1.5.	Glustin – pioglitazone – EMEA/H/C/000286.....	38
9.1.6.	Pioglitazone Teva Pharma – pioglitazone – EMEA/H/C/002410.....	38
9.1.7.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0129.....	39
9.1.8.	Comirnaty – tozinameran - EMEA/H/C/005735/SOB/043; SOB/044	39
9.1.9.	Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0016.....	39
9.1.10.	Onpattro - patisiran – Orphan - EMEA/H/C/004699/II/0025	40
9.1.11.	Carbaglu - carglumic acid - EMEA/H/C/000461/II/0044	40
9.1.12.	Imfinzi – durvalumab - EMEA/H/C/004771/II/0034.....	40
9.1.13.	Prialt - ziconotide - EMEA/H/C/000551/II/0068	41
10.	Referral procedures	41
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	41
10.1.1.	Rubraca - rucaparib - EMEA/H/A-20/1518/C/4272/0033.....	41
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004	42
10.2.1.	Update on Q&A for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev.6)	42
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	42
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	43
10.4.1.	Rambis - EMEA/H/A-29(4)/1519.....	43
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	43

10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	43
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	43
10.7.1.	Synchron Research Services – various – EMEA/H/A-31/1515	43
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	44
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/ 2003	44
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	44
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/ 2008	44
11.	Pharmacovigilance issue	44
11.1.	Early Notification System	44
12.	Inspections	44
12.1.	GMP inspections	44
12.2.	GCP inspections	45
12.3.	Pharmacovigilance inspections.....	45
12.4.	GLP inspections	45
13.	Innovation Task Force	45
13.1.	Minutes of Innovation Task Force.....	45
13.2.	Innovation Task Force briefing meetings.....	45
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	45
13.4.	Nanomedicines activities	45
14.	Organisational, regulatory and methodological matters	45
14.1.	Mandate and organisation of the CHMP	45
14.1.1.	Election of Co-opted Member	45
14.1.2.	Vote by proxy	46
14.2.	Coordination with EMA Scientific Committees.....	46
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	46
14.2.2.	Paediatric Committee (PDCO).....	46
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	46
14.3.1.	Biologics Working Party (BWP)	46
14.3.2.	Scientific Advice Working Party (SAWP)	47
14.3.3.	Appointment of expert for the Oncology Working Party (ONCWP)	47
14.3.4.	Non-clinical Working Party (NcWP).....	47
14.3.5.	CMDh question to Non-clinical Working Party (NcWP)	47
14.3.6.	Quality Working Party (QWP) – Nomination of new alternate.....	47

14.3.7.	CMDh question to Quality Working Party (QWP)	48
14.4.	Cooperation within the EU regulatory network	48
14.5.	Cooperation with International Regulators.....	48
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	48
14.7.	CHMP work plan	48
14.8.	Planning and reporting	48
14.8.1.	Update of the Business Pipeline report for the human scientific committees	48
14.9.	Others	48
15.	Any other business	49
15.1.	AOB topic.....	49
15.1.1.	Update on COVID-19	49
15.1.2.	Finalisation of the Companion Diagnostics (CDx) consultation procedure	49
15.1.3.	Update on timetables for modified COVID-19 vaccines	49
List of participants		49
Explanatory notes		56

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 20-23 June 2022.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 16-19 May 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 13 June 2022.

The CHMP adopted the minutes of the May Plenary meeting as well as the minutes from the June PROM meeting.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. Sunlenca - lenacapavir - EMEA/H/C/005638

Gilead Sciences Ireland Unlimited Company; treatment of human immunodeficiency virus type 1 (HIV-1) infection

Scope: Oral explanation

Action: Oral explanation to be held on 21 June 2022 at 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 16.12.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.1.2. maribavir - Orphan - EMEA/H/C/005787

Takeda Pharmaceuticals International AG Ireland Branch; treatment of cytomegalovirus (CMV) infection

Scope: Oral explanation

Action: Oral explanation to be held on 21 June 2022 at 14:00

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 14.10.2021.

An oral explanation was held on 21 June 2022. The presentation by the applicant focused on the clinical data in support of the application.

See 3.2

2.1.3. fosdenopterin - Orphan - EMEA/H/C/005378

Comharsa Life Sciences Ltd; treatment of molybdenum cofactor deficiency type A

Scope: Oral explanation

Action: Oral explanation to be held on 22 June 2022 at 15:30

List of Outstanding Issues adopted on 20.04.2022. List of Questions adopted on 22.02.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.4. [Pepaxti - melphalan flufenamide - Orphan - EMEA/H/C/005681](#)

Oncopeptides AB; treatment of multiple myeloma

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 21 June 2022 at 11:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022, 24.03.2022. List of Questions adopted on 16.09.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.2. **Re-examination procedure oral explanations**

No items

2.3. **Post-authorisation procedure oral explanations**

No items

2.4. **Referral procedure oral explanations**

No items

3. **Initial applications**

3.1. **Initial applications; Opinions**

3.1.1. [COVID-19 Vaccine \(inactivated, adjuvanted\) Valneva - COVID-19 vaccine \(inactivated, adjuvanted, adsorbed\) - EMEA/H/C/006019](#)

Valneva Austria GmbH; indicated for active immunisation against coronavirus disease 2019 (COVID-19)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that SARS-CoV-2 virus (inactivated) Wuhan strain hCoV-19/Italy/INMI1-Isl/2020 is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.2. Sunlenca - lenacapavir - EMEA/H/C/005638

Gilead Sciences Ireland Unlimited Company; treatment of human immunodeficiency virus type 1 (HIV-1) infection

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 16.12.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that lenacapavir is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.3. Pepaxti - melphalan flufenamide - Orphan - EMEA/H/C/005681

Oncopeptides AB; treatment of multiple myeloma

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022, 24.03.2022. List of Questions adopted on 16.09.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.4. [Ranivisio - ranibizumab - EMEA/H/C/005019](#)

Midas Pharma GmbH; treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation (CNV)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 22 June 2022.

The summary of opinion was circulated for information.

3.1.5. [Rayvow - lasmiditan - EMEA/H/C/005332](#)

Eli Lilly Nederland B.V.; acute treatment of migraine with or without aura in adults

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.12.2021, 16.09.2021, 22.07.2021. List of Questions adopted on 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that lasmiditan is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.6. Roctavian - valoctocogene roxaparvovec - PRIME - Orphan - ATMP - EMEA/H/C/005830

BioMarin International Limited; treatment of severe haemophilia A

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 18.03.2022. List of Questions adopted on 05.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that valoctocogene roxaparvovec is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 June 2022.

The summary of opinion was circulated for information.

3.1.7. Scemblix - asciminib - Orphan - EMEA/H/C/005605

Novartis Europharm Limited; treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that asciminib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 22 June 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.8. Vegzelma - bevacizumab - EMEA/H/C/005534

Celltrion Healthcare Hungary Kft.; Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 24.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP noted the letter of recommendation dated 21 June 2022.

The CHMP adopted the similarity assessment report.

3.1.9. Vyvgart - efgartigimod alfa - Orphan - EMEA/H/C/005849

Argenx; treatment of generalised Myasthenia Gravis (gMG)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that efgartigimod alfa is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 23 June 2022.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. doxorubicin hydrochloride - EMEA/H/C/005330

treatment of breast cancer, treatment of ovarian cancer, treatment of multiple myeloma, treatment of AIDS related Kaposi's sarcoma

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 28.05.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.2. dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 12.11.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee endorsed the PKWP response to the CHMP List of Questions to the PKWP on Dabigatran Etexilate Accord.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.3. dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362

prevention of dengue disease

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 24.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The CHMP agreed on the need to consult a SAG and adopted a list of questions to this group.

3.2.4. sutimlimab - Orphan - EMEA/H/C/005776

Genzyme Europe BV; treatment of haemolysis in adult patients with cold agglutinin disease (CAD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. maralixibat - Orphan - EMEA/H/C/005857

Mirum Pharmaceuticals International B.V.; Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. maribavir - Orphan - EMEA/H/C/005787

Takeda Pharmaceuticals International AG Ireland Branch; treatment of cytomegalovirus (CMV) infection

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 14.10.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.7. tirzepatide - EMEA/H/C/005620

treatment of adults with type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. fosdenopterin - Orphan - EMEA/H/C/005378

Comharsa Life Sciences Ltd; treatment of molybdenum cofactor deficiency type A

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 20.04.2022. List of Questions adopted on 22.02.2022.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.9. iodine (131I) omburtamab - Orphan - EMEA/H/C/005499

Y-Mabs Therapeutics A/S; treatment of neuroblastoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155

prevention of dengue disease

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 24.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The CHMP agreed on the need to consult a SAG and adopted a list of questions to this group.

3.2.11. teriflunomide - EMEA/H/C/005962

treatment of multiple sclerosis (MS)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.12. teriparatide - EMEA/H/C/005793

treatment of osteoporosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. ranibizumab - EMEA/H/C/005617

treatment of neovascular age-related macular degeneration (AMD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901

Amylyx Pharmaceuticals EMEA B.V.; treatment of amyotrophic lateral sclerosis (ALS)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

3.3.2. gadopichlenol - EMEA/H/C/005626

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. dabigatran etexilate - EMEA/H/C/005922

prevention of venous thromboembolic events

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. dapagliflozin - EMEA/H/C/006006

treatment of type 2 diabetes mellitus, heart failure and chronic kidney disease

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. pegunigalsidase alfa - Orphan - EMEA/H/C/005618

Chiesi Farmaceutici S.p.A.; treatment of Fabry disease

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. daprodustat - EMEA/H/C/005746

treatment of anaemia associated with chronic kidney disease (CKD) in adults

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. sitagliptin / metformin hydrochloride - EMEA/H/C/005778

treatment of type 2 diabetes mellitus

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. SARS-CoV-2 prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754

Active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. filgrastim - EMEA/H/C/005888

Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. sirolimus - Orphan - EMEA/H/C/005896

Plusultra pharma GmbH, Treatment of angiofibroma associated with tuberous sclerosis complex

Scope: Letter by the applicant dated 29.05.2022 requesting an extension to the clock stop to respond to the list of questions adopted in April 2022.

Action: For adoption

List of Questions adopted on 22.04.2022. The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2022.

3.4.2. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165

indicated for in vitro labelling of kits for radiopharmaceutical preparation

Scope: Letter by the applicant dated 08 June 2022 requesting an extension to the clock stop to respond to the list of questions adopted in December 2021.

Action: For adoption

List of Questions adopted on 16.12.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in December 2021.

3.4.3. octreotide - Orphan - EMEA/H/C/005826

Amryt Pharmaceuticals DAC; treatment of acromegaly

Scope: Letter by the applicant dated 07 June 2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in May 2022.

Action: For adoption

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in May 2022.

3.4.4. pemetrexed - EMEA/H/C/005848

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: Letter by the applicant dated 10 June 2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in May 2022.

Action: For adoption

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to

respond to the list of outstanding issues adopted in May 2022.

3.4.5. [surufatinib - EMEA/H/C/005728](#)

treatment of progressive neuroendocrine tumours

Scope: Letter by the applicant dated 27 May 2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

3.4.6. [sorafenib - EMEA/H/C/005921](#)

treatment of hepatocellular carcinoma and renal cell carcinoma

Scope: Request for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

The CHMP agreed to the request for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

3.5. **Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004**

3.5.1. [Tuznue - trastuzumab - EMEA/H/C/005066](#) / [Hervelous - trastuzumab - EMEA/H/C/005880](#)

Prestige Biopharma Belgium, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: request for re-examination

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion: 19.05.2022. List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

The CHMP noted the request for re-examination.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Procysbi - mercaptamine - Orphan - EMEA/H/C/002465/X/0035

Chiesi Farmaceutici S.p.A.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form associated with two new strengths (75 and 300 mg gastro-resistant granules). The RMP (version 7.2) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

No items

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G

Eli Lilly Nederland B.V.

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC
Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 6 months to 17 years) based on study 4 (H6D-MC-LVHV [LVHV]) - A 24-week placebo-controlled efficacy and safety study with an open-label long-term extension phase. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The paediatric indication is applicable to the new and all existing presentations. The Package Leaflet and Labelling are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template and editorial changes have been implemented. The RMP (version 9.1) is updated in accordance."

Letter by the applicant dated 06.06.2022 requesting an extension to the clock stop to respond to the list of questions adopted in May 2022.

Action: For adoption

List of Questions adopted on 19.05.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in May 2022.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Buvidal - buprenorphine - EMEA/H/C/004651/II/0017

Camurus AB

Rapporteur: Peter Kiely, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Tiphaine Vaillant

Scope: "To add the new therapeutic indication of treatment of moderate to severe chronic

pain in patients with opioid dependence. As a consequence, sections 4.1, 4.2, 4.5, 5.1 and 6.6 of the SmPC and sections 1, 3 and Instruction for use of the PL are updated accordingly. The updated RMP version 2.1 has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information (with a specific timetable).

5.1.2. [Crysvita - burosumab - Orphan - EMEA/H/C/004275/II/0023](#)

Kyowa Kirin Holdings B.V.

Rapporteur: Kristina Dunder, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: “Extension of indication to include treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults, based on data from two ongoing open-label clinical studies, UX023T-CL201 and KRN23-002, in adults with TIO (144-week data and 88-week data are available, respectively). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated and the Package Leaflet is updated accordingly. An updated RMP version 6.0 was agreed during the procedure. The MAH also applied for one additional year of market protection.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.3. [Dupixent - dupilumab - EMEA/H/C/004390/II/0060](#)

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola

Scope: “Extension of indication to include treatment of atopic dermatitis in paediatric patients from 6 months to <6 years of age based on final results from study R668-AD-1539; this is a phase 2/3 study investigating the pharmacokinetics, safety and efficacy of dupilumab in patients aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated.

The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.4. [Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0012](#)

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC

Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: “Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu based on final results from studies DS8201 A J202 (DESTINY Gastric01) and DS8201-A-U205 (DESTINY Gastric02); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced. Version 1.1 of the RMP has also been submitted.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for extended market protection.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.5. [Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0014](#)

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC

Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: “Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.6. Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0001

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen, based on interim results from study D8851C00001 (TACKLE); this is an ongoing, randomized, double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of a single 600 mg dose of AZD7442 (× 2 IM injections) compared with matching placebo for the treatment of mild to moderate COVID-19 in non-hospitalised adults. As a consequence, sections 4.1, 4.2, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 2 Succession 1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, some minor changes to the PI have been implemented in line with the latest Anticancer Guidelines Recommendations. Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.8. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0070

Janssen-Cilag International N.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients based on efficacy and safety data from phase 3 study GLOW and phase 2 study CAPTIVATE. The SmPC is revised to reflect the information on the combination with venetoclax. The PL is updated accordingly. The RMP version 18.4 has been submitted. Justification to support one year extension of the marketing protection period is included in the submission." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.9. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0073

Janssen-Cilag International N.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation, based on final results from the category 3 study PCI-32765MCL3002 (SHINE); this is a randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with BR in subjects with newly diagnosed MCL. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 19.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.10. Kerendia - finerenone - EMEA/H/C/005200/II/0001/G

Bayer AG

Rapporteur: Kristina Dunder, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes, based on results from study 17530 (FIGARO-DKD); a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC is being updated and the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC.

The updated RMP version 2.1 has also been submitted.

Update of the SmPC section 5.2 based on the results of study 21429, a phase 1 drug interaction study of finerenone with rosuvastatin. The CSR PH-42032 was already submitted within the response to Day 180 List of Outstanding Issues of the initial MAA.

Submission of the results of study 21325, a phase 1 bioequivalence study assessing BE between finerenone 2 x 10 mg tablets and 20 mg tablet in Japanese healthy male adult participants (required by the Japanese PMDA)."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.11. Libtayo - cemiplimab - EMEA/H/C/004844/II/0026

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include monotherapy treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy for Libtayo; sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G

Teva B.V.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age-appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC were updated. The Package Leaflet was updated in accordance. Version 14.1 of the RMP has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI was brought in line with the latest QRD template version 10.2."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022, 14.10.2021, 12.11.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.13. Lynparza - olaparib - EMEA/H/C/003726/II/0051/G

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include adjuvant treatment of breast cancer for Lynparza (for tablets); as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. In addition, section 4.8 of the SmPC for Lynparza hard capsules is revised based on the updated safety data analysis. The Package Leaflet is updated in accordance. Version 23 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.14. Nubeqa - darolutamide - EMEA/H/C/004790/II/0009

Bayer AG

Rapporteur: Alexandre Moreau, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel, based on final results from study 17777 (ARASENS); this is a randomized, double-blind, placebo-controlled Phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is also requesting one additional year of market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for additional market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.15. [Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0009](#)

Novavax CZ, a.s.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC
Rapporteur: Brigitte Keller-Stanislowski

Scope: "Extension of indication to include use in adolescents 12 to 17 years of age for Nuvaxovid, based on data from study 2019nCoV-301, a Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to evaluate the efficacy, safety, and immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M Adjuvant in Adult Participants $\geq$ 18 Years with a Paediatric Expansion in Adolescents (12 to < 18 Years); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.16. [Opdivo - nivolumab - EMEA/H/C/003985/II/0117](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislowski

Scope: "Extension of indication to include OPDIVO in combination with platinum-based chemotherapy for neoadjuvant treatment of adult patients with resectable Stage IB-IIIA non-small cell lung cancer (NSCLC), based on results from study CA209816; a randomised,

open-label, phase 3 trial of nivolumab plus ipilimumab or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in early-stage NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 27.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the wording of the indication.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. [Reblozyl - luspatercept - Orphan - EMEA/H/C/004444/II/0009](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Daniela Philadelphia, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Jean-Michel Dogné

Scope: "C.I.6 (Extension of indication)

Extension of indication in β -thalassaemia to include adult patients with non-transfusion dependent β -thalassaemia (NTDT) for Reblozyl; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects and the wording of the indication.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

The CHMP agreed to consult a SAG and adopted a list of questions to this expert group.

5.1.18. [Rinvoq - upadacitinib - EMEA/H/C/004760/II/0016](#)

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs), based on the final clinical study report from the pivotal study M19-944 study 2 (nr-axSpA); a randomized, double-blind, phase III study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with nr-axSpA who completed the double-blind period on study drug. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. A revised RMP version 8.0 is adopted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information

5.1.19. [Spikevax - elasomeran - EMEA/H/C/005791/II/0067](#)

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include immunisation of paediatric individuals from 6 months through 5 years of age based on results from the study P204 (KidCove); this is a phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. The MAH also took the opportunity to implement minor editorial changes in the product information. The submission includes a revised RMP version 4.1."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects as well as the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.20. [Ultomiris - ravulizumab - EMEA/H/C/004954/II/0026](#)

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adult patients with generalised myasthenia gravis (gMG). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 and 6.6 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPC and package leaflet. The Applicant also requested 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects and the request for extension of market protection.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.21. Xalkori - crizotinib - EMEA/H/C/002489/II/0072

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of paediatric patients (age ≥ 6 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for Xalkori based on the results from studies ADVL0912 and A8081013; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the ATC code for crizotinib. Moreover, the MAH took the opportunity to implement a minor change in the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022, 16.09.2021.

The Committee discussed the issues identified in this application, concerning the wording of the indication.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.22. Xydalba - dalbavancin - EMEA/H/C/002840/II/0043

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene

Scope: "Extension of indication to the paediatric population (aged 3 months to < 18 years) for the treatment of ABSSSI based on the interim results from the safety and efficacy Phase 3 study DUR001-306, together with data from 3 Phase 1 PK studies (A8841004, DUR001-106, and DAL-PK-02). Consequently, the sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC were updated. The Package Leaflet has been updated accordingly. In addition, the applicant has taken the opportunity to make minor editorial amendments and QRD updates (v10.2) to the SmPC/PIL. Version 7.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects as well as the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.23. Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0036

Merck Sharp & Dohme B.V.

Rapporteur: Ingrid Wang, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include treatment of paediatric patients aged birth to less than 18 years for Zerbaxa, based on final results from studies MK-7625A-034 (A Phase 2, Randomized, Active Comparator-Controlled, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Paediatric Subjects with Complicated Urinary Tract Infection, Including Pyelonephritis) and MK-7625A-035 (A Phase 2, Randomized, Active Comparator-Controlled, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Paediatric Subjects with Complicated Intra-Abdominal Infection).

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022, 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G

Karyopharm Europe GmbH

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: A similarity assessment report was adopted via written procedure on 31 May 2022.

Action: For information

The CHMP noted the similarity assessment report, which was adopted via written procedure.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006078

detection of PD-L1 protein

Corresponding medicinal product(s): Keytruda – Pembrolizumab – EMEA/H/C/003820;
Libtayo – Cemiplimab - EMEA/H/C/004844

Scope: Opinion

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

No topics

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 7 recommendations for eligibility to PRIME: 3 were accepted and 4 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Cuprior - trientine - EMEA/H/C/004005/R/0018

Orphan

Rapporteur: Jayne Crowe, Co-Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Renewal of Marketing Authorisation

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.2. Elzonris - tagraxofusp – Orphan - EMEA/H/C/005031/II/0009

Stemline Therapeutics B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Submission of the final report from study 20255431 (CRL-263114) 'Characterisation of fixed choroid plexus samples from primate study MPI-2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain

barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The RMP version 2.0 has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 13.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.3. Episalvan – birch bark extract – EMEA/H/C/003938

Amryt GmbH; treatment of partial thickness wounds

Rapporteur: Kristina Dunder, Co-Rapporteur: Elita Poplavska

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.4. Cetrotide - cetrorelix – EMEA/H/C/000233

Merck Europe B.V.

Rapporteur: Martina Weise, Co-Rapporteur: Nevenka Trsinar Brodt

Scope: DHPC and communication, shortage of the medicinal product.

Action: For adoption

The CHMP adopted the DHPC and communication plan.

9.1.5. Glustin – pioglitazone – EMEA/H/C/000286

Takeda Pharma A/S; treatment of type 2 diabetes

Rapporteur: Peter Kiely, Co-Rapporteur: Bruno Sepodes

Scope: Withdrawal of marketing authorisation

Action: For information

CHMP noted the withdrawal of marketing authorisation.

9.1.6. Pioglitazone Teva Pharma – pioglitazone – EMEA/H/C/002410

Teva B.V.; treatment of type 2 diabetes mellitus

Rapporteur: Peter Kiely

Scope: Withdrawal of marketing authorisation

Action: For information

CHMP noted the withdrawal of marketing authorisation.

9.1.7. Comirnaty - tozinameran - EMEA/H/C/005735/II/0129

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC of Comirnaty 10 µg concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007 listed as a specific obligation in the Annex II; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.8. Comirnaty – tozinameran - EMEA/H/C/005735/SOB/043; SOB/044

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race

Scope: Update on the status of the clinical specific obligations.

Action: For adoption

The CHMP adopted the conclusions on the status of the clinical specific obligations.

9.1.9. Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0016

International Partnership for Microbicides Belgium AISBL

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Jan Neuhauser

Scope: "Update of the Annex II for Dapivirine in order to replace the current PAES: Phase IV, open label, multicentre efficacy trial in healthy HIV-negative young women age 18-25 years (IPM 055), listed as a category 1 study in the RMP, with the implementation study: Dapivirine vaginal ring implementation in a real-world setting in young women. An updated RMP version 0.9 was submitted as part of the application."

Action: For adoption

Request for Supplementary Information adopted on 07.04.2022.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.10. Onpattro - patisiran – Orphan - EMEA/H/C/004699/II/0025

Alnylam Netherlands B.V.

Rapporteur: Kristina Dunder

Scope: "Update of sections 4.2 and 5.1 of the SmPC based on interim results from study ALN-TTR02-006 listed as a category 3 study in the RMP; this is a multicenter, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial amyloidotic polyneuropathy who have completed a prior clinical study with patisiran. In addition, the MAH took the opportunity to update section 3 of the SmPC in order to update the pH."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.11. Carbaglu - carglumic acid - EMEA/H/C/000461/II/0044

Recordati Rare Diseases

Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Update of sections 4.2 and 4.4 of the SmPC in order to include information on the impact of renal impairment on systemic exposures to Carbaglu following a FDA request, based on final results from study A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Carbaglu in Subjects with Normal and Varying Degrees of Impaired Renal Function. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.12. Imfinzi – durvalumab - EMEA/H/C/004771/II/0034

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia

Scope: "Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes.

In addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of the SmPC.”

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 20.01.2022, 21.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.13. [Prialta - ziconotide - EMEA/H/C/000551/II/0068](#)

ESTEVE Pharmaceuticals GmbH

Rapporteur: Christophe Focke

Scope: “Update of section 4.2 of the SmPC to adjust the posology regimen. Update of sections 4.2, 4.3, 4.4 and 4.8 to add information regarding the increased risk of suicide. Update of section 5.1 to add a paragraph regarding responsive daily dose. The Package Leaflet to be updated accordingly. In addition, the MAH took the opportunity to update QRD template to v.10.2 Rev.1 and implement editorial changes in SmPC, PL, and Labelling.”

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 27.01.2022, 16.09.2021

The Committee confirmed that all issues previously identified in this application had been addressed. The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. [Rubraca - rucaparib - EMEA/H/A-20/1518/C/4272/0033](#)

Clovis Oncology Ireland Limited

Referral Rapporteur: Blanca Garcia-Ochoa, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: List of outstanding issues

Action: For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of the centrally authorised medicinal product Rubraca (rucaparib) in the approved ‘3rd line or more treatment’.

EMA has started a review of the cancer medicine Rubraca (rucaparib camsylate) when it is used to treat cancer of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after platinum-based chemotherapy and who can no longer have these medicines.

The review follows preliminary results indicating that overall survival was shorter in these patients than in those receiving chemotherapy. These results come from the ongoing ARIEL4 study¹ comparing Rubraca with chemotherapy in patients with high-grade cancer of the ovary, fallopian tubes or peritoneum with a BRCA mutation whose cancer has come back after chemotherapy.

The CHMP adopted a list of outstanding issues with a specific timetable.

Submission of responses: 29.06.2022

Re-start of the procedure: 04.07.2022

Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 07.07.2022

Comments: 12.07.2022

Updated Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 14.07.2022

CHMP list of outstanding issues or opinion: July 2022 CHMP

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Update on Q&A for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev.6)

Update of questions 5, 10 and 14 to highlight to MAHs risks from formation of nitroso-API impurities, publication of a limit for N-nitroso-dabigatran, and guidance on a template to supplement the nitrosamine risk assessment for new and on-going MAAs.

Action: For adoption

CHMP adopted the updated Q&A for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Rambis - EMEA/H/A-29(4)/1519

Adamed Pharma S.A.

Rapporteur: Ewa Balkowiec Iskra, Co-Rapporteur: Ondrej Slanar

Scope: Appointment of Rapporteurs, list of questions, timetable

Action: For adoption

Decentralised procedure number: PL/H/0758/001-006/DC, notification by the Agency of Poland dated 30 May 2022 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC

The CHMP appointed Ewa Balkowiec Iskra as Rapporteur and Ondrej Slanar as Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Start of procedure (CHMP): June 2022 CHMP

List of Questions: 23.06.2022

Submission of responses: 28.07.2022

Re-start of the procedure: 18.08.2022

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 26.08.2022

Comments: 02.09.2022

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 08.09.2022

CHMP list of outstanding issues or CHMP opinion: September 2022 CHMP

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.7.1. Synchron Research Services – various – EMEA/H/A-31/1515

Various MAHs

Re-examination Referral Rapporteur: John Joseph Borg, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Appointment of re-examination rapporteurs, draft timetable

Action: For adoption

The CHMP appointed John Joseph Borg as re-examination Rapporteur and Paula Boudewina van Hennik as re-examination Co-Rapporteur.

The CHMP noted the draft timetable.

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

June 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose

of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Election of Co-opted Member

Election of CHMP co-opted member in light of the expiry of mandate of co-opted member Christian Gartner on 23 June 2022.

Agreed areas of expertise: medical statistics.

Nomination(s) received

Action: For election

The CHMP re-elected Christian Gartner as co-opted member in area of expertise medical statistics.

14.1.2. Vote by proxy

None

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for June 2022

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at June 2022 PDCO

Action: For information

The CHMP noted the information.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Sean Barry

Reports from BWP June 2022 meeting to CHMP for adoption:

- 15 reports on products in scientific advice and protocol assistance
- 10 reports on products in pre-authorisation procedures
- 5 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 07-10 June 2022. Table of conclusions

Action: For information

Scientific advice letters: Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

14.3.3. Appointment of expert for the Oncology Working Party (ONCWP)

Chair: Pierre Demolis

A new member should be appointed to the Oncology Working Party following the resignation of Sigrid Klaar.

Action: For adoption

The CHMP appointed Nuno Sousa as new member to the Oncology Working Party.

14.3.4. Non-clinical Working Party (NcWP)

Chairs: Susanne Brendler-Schwaab, Karen van Malderen

NcWP position on the acceptable intake (AI) for N-nitrosodabigatran based on lifetime daily exposure including information on the points of departure and methodology used.

Action: For adoption

The CHMP adopted the NcWP position.

14.3.5. CMDh question to Non-clinical Working Party (NcWP)

Chairs: Susanne Brendler-Schwaab, Karen van Malderen

CMDh question to NcWP on inclusion of disposal information in the SmPC information in the SmPC PL of topical diclofenac (and other NSAIDs) formulations to have a confirmation on the proposed wording and to have a recommendation concerning extrapolation to other topical (NSAID).

Action: For adoption

The CHMP endorsed the question to NcWP.

14.3.6. Quality Working Party (QWP) – Nomination of new alternate

Chair: Blanka Hirschlerova

Nomination of new QWP alternate Silvia Carstoiu replacing Marina Fetita Popescu representing Romania.

Action: For adoption

CHMP endorsed the nomination of the new QWP alternate Silvia Carstoiu replacing Marina Fetita Popescu representing Romania.

14.3.7. CMDh question to Quality Working Party (QWP)

Chair: Blanka Hirschlerova

CMDh question to QWP and GMP IWG on how vehicle tank containers for medicinal gases should be classified in terms of packaging of the finished product.

Action: For adoption

The CHMP endorsed the question to QWP.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

2022 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

The CHMP noted the information.

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the information.

15.1.2. Finalisation of the Companion Diagnostics (CDx) consultation procedure

Further to public consultation on the draft version published in December 2021, the EMA guidance on the CDx consultation (EMA/198592/2022) has been updated and is now final. The CHMP/CAT AR CDx template as well as the application forms for both initial and follow-up procedures have also been updated.

Action: For adoption

The CHMP adopted the Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics.

15.1.3. Update on timetables for modified COVID-19 vaccines

Action: For information

CHMP noted the update on timetables for modified COVID-19 vaccines.

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 20-23 June CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Helena Panayiotopoulou	Member	Cyprus	No interests declared	COVID-19 vaccines
Emilia Mavrokordatou	Alternate	Cyprus	No participation in final deliberations and voting on:	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Aaron Sosa Mejia	Alternate	Denmark	No restrictions applicable to this meeting	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähtenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Grzegorz Cessak	Alternate	Poland	No participation in final deliberations and voting on:	COVID-19 vaccines
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jose Caballero Corbalán	Expert	Sweden	No restrictions applicable to this meeting	
Vincent Gazin	Expert	France	No interests declared	
Irene Bachmann	Expert	Germany	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Sabine Mayrhofer	Expert	Germany	No interests declared	
Paula Cardona Xuereb	Expert	Malta	No interests declared	
Karl Katholnig	Expert	Austria	No restrictions applicable to this meeting	
Harald Bernsteiner	Expert	Austria	No interests declared	
Christoph Mueck	Expert	Austria	No interests declared	
Martin Walter	Expert	Austria	No interests declared	
Ilona Reischl	Expert	Austria	No interests declared	
Kairi Rooma	Expert	Estonia	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	
Jorg Engelbergs	Expert	Germany	No interests declared	
Alexandru Mihail Simion	Expert	Belgium	No interests declared	
Olga Kholmanskikh	Expert	Belgium	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Paula Contreras Alarcón	Expert	Spain	No participation in discussion, final deliberations and voting on:	Rinvoq - upadacitinib - EMEA/H/C/004760/II/0016
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Mas Parra Paloma	Expert	Spain	No restrictions applicable to this meeting	
Lucia Lopez-Anglada Fernandez	Expert	Spain	No interests declared	
Agustin Portela Moreira	Expert	Spain	No interests declared	
Jessica Harskamp	Expert	Netherlands	No interests declared	
Laura Rodwell	Expert	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Elly Vereyken	Expert	Netherlands	No restrictions applicable to this meeting	
Emmely de Vries	Expert	Netherlands	No interests declared	
Nienke Rodenhuis	Expert	Netherlands	No interests declared	
Patrick Vrijlandt	Expert	Netherlands	No interests declared	
Stephanie Buchholz	Expert	Germany	No interests declared	
Sofia Kapanadze	Expert	Germany	No restrictions applicable to this meeting	
Anne Isabel Roth	Expert	Germany	No interests declared	
Geraldine O'Dea	Expert	Ireland	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert	Italy	No participation in discussion, final deliberations and voting on:	pegunigalsidase alfa - Orphan - EMEA/H/C/005618 Procysbi - mercaptamine - Orphan - EMEA/H/C/002465/X/0035
Angelo Molinaro	Expert	Italy	No interests declared	
Cristina Migali	Expert	Italy	No interests declared	
Gabriella Passacuale	Expert	Italy	No interests declared	
Valentina Conti	Expert	Italy	No interests declared	
Pia Rivetti di Val Cervo	Expert	Italy	No interests declared	
Simona Teodosiu	Expert	France	No interests declared	
Nathalie Morgensztejn	Expert	France	No interests declared	
Kristin Skougaard	Expert	Denmark	No interests declared	
Kristina Bech Jensen	Expert	Denmark	No interests declared	
Mette Toftegaard Madsen	Expert	Denmark	No interests declared	
Lene Weber Vestermark	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Line Praest Lauridsen	Expert	Denmark	No restrictions applicable to this meeting	
Anne Hasle Buur	Expert	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Charlotte Hejl	Expert	Denmark	No restrictions applicable to this meeting	
Sine Buhl Naess-Schmidt	Expert	Denmark	No restrictions applicable to this meeting	
Nanna Borup Johansen	Expert	Denmark	No interests declared	
Claus Stage	Expert	Denmark	No restrictions applicable to this meeting	
Thadeus Bao Quan Nguyen	Expert	Denmark	No interests declared	
Karin Fjordén	Expert	Sweden	No participation in final deliberations and voting on:	Imbruvica - ibrutinib - EMEA/H/C/003791/II/0070 Imbruvica - ibrutinib - EMEA/H/C/003791/II/0073
Daiana Vasilcanu	Expert	Sweden	No interests declared	
Tania Meier	Expert	Germany	No interests declared	
Anders Lignell	Expert	Sweden	No interests declared	
Maria Linnea Asp	Expert	Sweden	No restrictions applicable to this meeting	
Charlotte Anderberg	Expert	Sweden	No restrictions applicable to this meeting	
Stephanie Jambon	Expert	France	No interests declared	
Ingrid Schellens	Expert	Netherlands	No interests declared	
Maria Di Marzo	Expert	Italy	No interests declared	
Luisa Valer	Expert	Spain	No interests declared	
Lourdes Rodriguez Rojas	Expert	Spain	No interests declared	
Cristina Lucia Rueda Pérez	Expert	Spain	No restrictions applicable to this meeting	
Martina Schuessler-Lenz	Expert	Germany	No interests declared	
Filip Kukulski	Expert	Health Canada	No interests declared	
Mohit Khera	Expert	TGA Australia	No interests declared	
Megan Hickie	Expert	TGA Australia	No interests declared	
Deepak Rai	Expert	TGA Australia	No interests declared	
Sabine Eichinger	Expert	EMA	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
A representative from the European Commission attended the meeting.				
Meeting run with support from relevant EMA staff.				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section lists issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

28 July 2022
EMA/CHMP/602063/2022

Annex to 20-23 June 2022 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES	3
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES	3
B.1. Annual re-assessment outcomes	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	3
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	3
B.2.3. Renewals of Conditional Marketing Authorisations	5
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	5
B.4. EPARs / WPARs	9
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	11
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	11
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	17
B.5.3. CHMP-PRAC assessed procedures	38
B.5.4. PRAC assessed procedures.....	47
B.5.5. CHMP-CAT assessed procedures	53
B.5.6. CHMP-PRAC-CAT assessed procedures	54
B.5.7. PRAC assessed ATMP procedures	55
B.5.8. Unclassified procedures and worksharing procedures of type I variations	55
B.5.9. Information on withdrawn type II variation / WS procedure	57
B.5.10. Information on type II variation / WS procedure with revised timetable	58
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	58
B.6.1. Start of procedure for New Applications: timetables for information	58
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	59



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	60
B.6.4. Annual Re-assessments: timetables for adoption	62
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	62
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	64
B.6.7. Type II Variations scope of the Variations: Extension of indication	64
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	69
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	71
B.6.10. CHMP-PRAC assessed procedures.....	77
B.6.11. PRAC assessed procedures	79
B.6.12. CHMP-CAT assessed procedures	79
B.6.13. CHMP-PRAC-CAT assessed procedures.....	80
B.6.14. PRAC assessed ATMP procedures	81
B.6.15. Unclassified procedures and worksharing procedures of type I variations	81
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY.....	83
B.7.1. Yearly Line listing for Type I and II variations.....	83
B.7.2. Monthly Line listing for Type I variations.....	83
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	83
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)	83
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)	83
B.7.6. Notifications of Type I Variations (MMD only)	83
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)	83
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	83
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	83
E.1. PMF Certification Dossiers:.....	83
E.1.1. Annual Update.....	83
E.1.2. Variations:	83
E.1.3. Initial PMF Certification:.....	83
E.2. Time Tables – starting & ongoing procedures: For information	83
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	84
G. ANNEX G.....	84
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	84
G.2. PRIME.....	84
G.2.1. List of procedures concluding at 20-23 June 2022 CHMP plenary:	84
G.2.2. List of procedures starting in June 2022 for July 2022 CHMP adoption of outcomes	85
H. ANNEX H - Product Shared Mailboxes – e-mail address.....	85

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for June 2022: For adoption	Adopted
--	---------

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for June 2022: For adoption	Adopted
--	---------

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Lamzede - velmanase alfa - EMA/H/C/003922/S/0025, Orphan Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser	Positive Opinion adopted by consensus together with the CHMP assessment. The Marketing Authorisation remains under exceptional circumstances.
--	--

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Cuprior - trientine - EMA/H/C/004005/R/0018 Orphalan, Rapporteur: Jayne Crowe, Co- Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. See 9.1
Dupixent - dupilumab - EMA/H/C/004390/R/0053	Positive Opinion adopted by consensus together with the CHMP assessment report and

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Kimmo Jaakkola Request for Supplementary Information adopted on 22.04.2022, 27.01.2022.	translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Lacosamide Accord - lacosamide - EMEA/H/C/004443/R/0015 Accord Healthcare S.L.U., Generic, Generic of Vimpat, Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 22.04.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Miglustat Gen.Orph - miglustat - EMEA/H/C/004366/R/0022 Gen.Orph, Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.
NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/R/0056, Orphan MediWound Germany GmbH, Rapporteur: Janet Koenig, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Martin Huber	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
PREVYMIS - letermovir - EMEA/H/C/004536/R/0027, Orphan Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Kirsti Villikka	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Ritonavir Mylan - ritonavir - EMEA/H/C/004549/R/0015 Mylan Pharmaceuticals Limited, Generic, Generic of Norvir, Rapporteur: John Joseph Borg, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 19.05.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Tacforius - tacrolimus - EMEA/H/C/004435/R/0010 Teva B.V., Generic, Generic of Advagraf, Rapporteur: Daniela Philadelphia, PRAC	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available

Rapporteur: Ronan Grimes Request for Supplementary Information adopted on 19.05.2022.	information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
TOOKAD - padeliporfin - EMA/H/C/004182/R/0019 STEBA Biotech S.A, Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Maia Uusküla Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.

B.2.3. Renewals of Conditional Marketing Authorisations

Adakveo - crizanlizumab - EMA/H/C/004874/R/0008, Orphan Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
VITRAKVI - larotrectinib - EMA/H/C/004919/R/0024 Bayer AG, Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene Request for Supplementary Information adopted on 19.05.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its June 2022 meeting:	
EMA/H/C/PSUSA/00000086/202109 (alglucosidase alfa) CAPS: Myozyme (EMA/H/C/000636) (alglucosidase alfa), Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, "28/09/2019 To: 28/09/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the following adverse reactions with frequency not known: dyspepsia, dysphagia, transient skin discoloration, blister, palmar erythema, infusion

	site erythema, infusion site urticaria and hypoxia. The Package leaflet is updated accordingly.
EMA/H/C/PSUSA/00002652/202111 (rituximab) CAPS: Blitzima (EMA/H/C/004723) (rituximab), Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz MabThera (EMA/H/C/000165) (rituximab), Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia Rixathon (EMA/H/C/003903) (rituximab), Sandoz GmbH, Rapporteur: Jan Mueller- Berghaus Riximyo (EMA/H/C/004729) (rituximab), Sandoz GmbH, Rapporteur: Jan Mueller- Berghaus Ruxience (EMA/H/C/004696) (rituximab), Pfizer Europe MA EEIG, Rapporteur: Paula Boudewina van Hennik Truxima (EMA/H/C/004112) (rituximab), Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz, PRAC Rapporteur: Anette Kirstine Stark, "17/11/2020 To: 17/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.6 of the SmPC to amend a warning on breastfeeding and of section 4.8 of the SmPC to add the risk of serious viral infections with a frequency <Not known>. The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010171/202110 (para-aminosalicylic acid (centrally authorised product)) CAPS: Granupas (EMA/H/C/002709) (para-aminosalicylic acid), Eurocept International B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "07/10/2018 To: 07/10/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes: Update of section 4.5 of the SmPC to add an interaction of para-aminosalicylic acid and tenofovir. The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010449/202111 (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) CAPS: Genvoya (EMA/H/C/004042) (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide), Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Amelia Cupelli, "04/11/2020 To: 04/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 to amend the existing warning on nephrotoxicity. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010534/202110 (irinotecan (liposomal formulations)) CAPS: Onivyde pegylated liposomal (EMA/H/C/004125) (irinotecan hydrochloride trihydrate), Les Laboratoires Servier, Rapporteur: Filip Josephson, PRAC Rapporteur: David Olsen, "23/10/2020 To: 22/10/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to amend a warning/precaution regarding Hypersensitivity reactions and to add additional terms to the table of ADRs, and section 4.5 to add an interaction regarding flucytosine. The package leaflet is updated accordingly. In addition, the RMP (version 4.0) is updated accordingly.
EMA/H/C/PSUSA/00010575/202111 (tenofovir alafenamide) CAPS: Vemlidy (EMA/H/C/004169) (tenofovir alafenamide), Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Amelia Cupelli, "09/11/2020 To: 09/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 to amend the existing warning on nephrotoxicity. The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010577/202111 (insulin glargine / lixisenatide) CAPS: Suliqua (EMA/H/C/004243) (insulin glargine / lixisenatide), sanofi-aventis groupe, Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, "21/11/2020 To: 21/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction delayed gastric emptying with a frequency rare. The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010588/202111 (tofacitinib) CAPS: Xeljanz (EMA/H/C/004214) (tofacitinib), Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "06/11/2020 To: 05/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning/precaution regarding hypoglycaemia.

	The package leaflet is updated accordingly. Update of section 4.4 of the SmPC to add a warning/precaution regarding retinal venous thrombosis and update of footnote under the ADR table in section 4.8 to indicate that venous thromboembolism also includes retinal venous thrombosis. The package leaflet is updated accordingly. Additionally, Annex II was updated to reflect removal of the important potential risk "increased exposure to XELJANZ when co-administered with CYP3A4 and CYP2C19 inhibitors", as proposed in the version 24.2 of the RMP submitted during the procedure. The final adopted RMP version is v. 29.1.
EMA/H/C/PSUSA/00010703/202110 (axicabtagene ciloleucel) CAPS: Yescarta (EMA/H/C/004480) (axicabtagene ciloleucel), Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark, "18/04/2021 To: 17/10/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction status epilepticus with a frequency of common. The Package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010723/202110 (durvalumab) CAPS: Imfinzi (EMA/H/C/004771) (durvalumab), AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: David Olsen, "01/05/2021 To: 31/10/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change: An update of section 4.8 of the SmPC to add the adverse reaction psoriasis with a frequency uncommon. The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010840/202111 (remdesivir) CAPS: Veklury (EMA/H/C/005622) (remdesivir), Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, "06/05/2021To: 06/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction anaphylactic shock with a

	frequency Not known. The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010848/202111 (onasemnogene abeparvovec) CAPS: Zolgensma (EMA/H/C/004750) (onasemnogene abeparvovec), Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, "24/05/2021 To: 23/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC with additional information on thrombocytopenia.
EMA/H/C/PSUSA/00010849/202111 (cefiderocol) CAPS: Fetcroja (EMA/H/C/004829) (cefiderocol), Shionogi B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber, "13/11/2020 To: 13/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reactions "blood creatinine increased" with a frequency "common" and "blood urea increased" with a frequency "uncommon". The package leaflet is updated accordingly. Update of section 4.8 of the SmPC to add the adverse reaction "neutropenia" with a frequency "not known". The package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010871/202111 (alpelisib) CAPS: Piqray (EMA/H/C/004804) (alpelisib), Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, "24/05/2021 To: 23/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of sections 4.2, 4.4 and 4.8 of the SmPC to add the adverse reactions colitis and angioedema with a frequency Not known. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

Cevenfacta - eptacog beta (activated) - EMA/H/C/005655 Laboratoire Francais du Fractionnement et des Biotechnologies, treatment and for the prevention of bleeding, New active substance	For information only. Comments can be sent to the PL in case necessary.
--	---

(Article 8(3) of Directive No 2001/83/EC)

**Ertapenem SUN - ertapenem -
EMA/H/C/005815**

SUN Pharmaceutical Industries (Europe) B.V.,
treatment of bacterial infections and prophylaxis
of surgical site infection following elective
colorectal surgery, Generic, Generic of Invanz,
Generic application (Article 10(1) of Directive No
2001/83/EC)

For information only. Comments can be sent to
the PL in case necessary.

**Ganirelix Gedeon Richter - ganirelix -
EMA/H/C/005641**

Chemical Works of Gedeon Richter Plc. (Gedeon
Richter Plc.), Prevention of premature
luteinising hormone (LH) surges in women
undergoing controlled ovarian hyperstimulation
(COH) for assisted reproduction techniques
(ART)., Generic, Generic of Orgalutran, Generic
application (Article 10(1) of Directive No
2001/83/EC)

For information only. Comments can be sent to
the PL in case necessary.

**Kinpeygo - budesonide -
EMA/H/C/005653, Orphan**

Calliditas Therapeutics AB, treatment of primary
immunoglobulin A (IgA) nephropathy, Hybrid
application (Article 10(3) of Directive No
2001/83/EC)

For information only. Comments can be sent to
the PL in case necessary.

**Sitagliptin/Metformin Hydrochloride
Accord - sitagliptin / metformin
hydrochloride - EMA/H/C/005850**

Accord Healthcare S.L.U., treatment of type 2
diabetes mellitus, Generic, Generic of Janumet,
Generic application (Article 10(1) of Directive No
2001/83/EC)

For information only. Comments can be sent to
the PL in case necessary.

**Sugammadex Fresenius Kabi -
sugammadex - EMA/H/C/005760**

Fresenius Kabi Deutschland GmbH, Reversal of
neuromuscular blockade induced by rocuronium
or vecuronium., Generic, Generic of Bridion,
Generic application (Article 10(1) of Directive No
2001/83/EC)

For information only. Comments can be sent to
the PL in case necessary.

**Upstaza - eladocagene exuparvovec -
EMA/H/C/005352, Orphan, ATMP**

PTC Therapeutics International Limited,
treatment of aromatic L-amino
aciddecarboxylase (AADDC) deficiency, New
active substance (Article 8(3) of Directive No
2001/83/EC)

For information only. Comments can be sent to
the PL in case necessary.

Xenpozyme - olipudase alfa -

For information only. Comments can be sent to

EMEA/H/C/004850, Orphan Genzyme Europe BV, treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) disease-modifying enzyme replacement therapy for long-term treatment of non-Central Nervous System, New active substance (Article 8(3) of Directive No 2001/83/EC)	the PL in case necessary.
Zokinvy - lonafarnib - EMEA/H/C/005271, Orphan EigerBio Europe Limited, treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Abevmy - bevacizumab - EMEA/H/C/005327/II/0009 Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0102/G, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Alymsys - bevacizumab - EMEA/H/C/005286/II/0010 Mabxience Research SL, Rapporteur: Christian Gartner Opinion adopted on 16.06.2022.	Positive Opinion adopted by consensus on 16.06.2022.
Ameluz - 5-aminolevulinic acid - EMEA/H/C/002204/II/0049/G Biofrontera Bioscience GmbH, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 10.06.2022, 14.10.2021.	Request for supplementary information adopted with a specific timetable.
BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0045, Orphan Amgen Europe B.V., Rapporteur: Alexandre	Positive Opinion adopted by consensus on 23.06.2022.

Moreau Opinion adopted on 23.06.2022. Request for Supplementary Information adopted on 22.04.2022.	
BLINCYTO - blinatumomab - EMA/H/C/003731/II/0047/G, Orphan Amgen Europe B.V., Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
Brintellix - vortioxetine - EMA/H/C/002717/II/0033 H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted on 02.06.2022.	Request for supplementary information adopted with a specific timetable.
COMIRNATY - tozinameran - EMA/H/C/005735/II/0124/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 10.06.2022.	Positive Opinion adopted by consensus on 10.06.2022.
COMIRNATY - tozinameran - EMA/H/C/005735/II/0130/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 02.06.2022.	Positive Opinion adopted by consensus on 02.06.2022.
COMIRNATY - tozinameran - EMA/H/C/005735/II/0131 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 23.06.2022.	Positive Opinion adopted by consensus on 23.06.2022.
Elaprase - idursulfase - EMA/H/C/000700/II/0098/G Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 10.06.2022, 07.04.2022.	Request for supplementary information adopted with a specific timetable.
Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMA/H/C/004993/II/0030 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 23.06.2022.	Positive Opinion adopted by consensus on 23.06.2022.
Hepcludex - bulevirtide - EMA/H/C/004854/II/0014/G, Orphan Gilead Sciences Ireland Unlimited Company,	Request for supplementary information adopted with a specific timetable.

Rapporteur: Filip Josephson Request for Supplementary Information adopted on 23.06.2022.	
Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0135 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 02.06.2022.	Request for supplementary information adopted with a specific timetable.
Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0136/G CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0050 Janssen-Cilag International N.V., Rapporteur: Christophe Focke Opinion adopted on 10.06.2022.	Positive Opinion adopted by consensus on 10.06.2022.
LIVOGIVA - teriparatide - EMEA/H/C/005087/II/0010 Theramex Ireland Limited, Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.
NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0117 Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
Odomzo - sonidegib - EMEA/H/C/002839/II/0041 Sun Pharmaceutical Industries Europe B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 23.06.2022. Request for Supplementary Information adopted on 24.03.2022.	Positive Opinion adopted by consensus on 23.06.2022.
Oyavas - bevacizumab - EMEA/H/C/005556/II/0009/G STADA Arzneimittel AG, Duplicate, Duplicate of Alymsys, Rapporteur: Christian Gartner Opinion adopted on 02.06.2022.	Positive Opinion adopted by consensus on 02.06.2022.
Polivy - polatuzumab vedotin -	Request for supplementary information adopted

EMEA/H/C/004870/II/0017/G, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 23.06.2022.	with a specific timetable.
Ruxience - rituximab - EMEA/H/C/004696/II/0011 Pfizer Europe MA EEIG, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
Simulect - basiliximab - EMEA/H/C/000207/II/0114/G Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Spectrila - asparaginase - EMEA/H/C/002661/II/0029 medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 02.06.2022.	Request for supplementary information adopted with a specific timetable.
Supemtek - quadrivalent influenza vaccine (recombinant, prepared in cell culture) - EMEA/H/C/005159/II/0007/G Sanofi Pasteur, Rapporteur: Jan Mueller- Berghaus Request for Supplementary Information adopted on 16.06.2022, 10.03.2022.	Request for supplementary information adopted with a specific timetable.
TAKHZYRO - lanadelumab - EMEA/H/C/004806/II/0030/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
Temozolomide SUN - temozolomide - EMEA/H/C/002198/II/0037 Sun Pharmaceutical Industries Europe B.V., Generic, Generic of Temodal, Rapporteur: Filip Josephson Opinion adopted on 02.06.2022.	Positive Opinion adopted by consensus on 02.06.2022.
Vaniqa - eflornithine - EMEA/H/C/000325/II/0056 Almirall S.A, Rapporteur: Peter Kiely Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 10.06.2022.

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0097

MCM Vaccine B.V., Rapporteur: Christophe Focke

Request for Supplementary Information adopted on 02.06.2022.

Request for supplementary information adopted with a specific timetable.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0071

AstraZeneca AB, Rapporteur: Sol Ruiz

Request for Supplementary Information adopted on 02.06.2022.

Request for supplementary information adopted with a specific timetable.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0074

AstraZeneca AB, Rapporteur: Sol Ruiz, "Type II C.I.11.b, To update Annex IIE to remove the specific obligation relating to provision of process validation data for the active substance and finished product (SO1) which has been fulfilled, and to change the date of the specific obligation relating to the provision of additional information on stability of the active substance and finished product (and review the finished product specifications following further manufacturing experience) from June 2022 to January 2023 (SO2)."

Opinion adopted on 23.06.2022.

Positive Opinion adopted by consensus on 23.06.2022.

Vimizim - elosulfase alfa - EMEA/H/C/002779/II/0037/G, Orphan

BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege

Opinion adopted on 23.06.2022.

Positive Opinion adopted by consensus on 23.06.2022.

Votrient - pazopanib - EMEA/H/C/001141/II/0071/G

Novartis Europharm Limited, Rapporteur: Aaron Sosa Mejia

Request for Supplementary Information adopted on 02.06.2022, 17.02.2022.

Request for supplementary information adopted with a specific timetable.

Wegovy - semaglutide - EMEA/H/C/005422/II/0001/G

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege

Positive Opinion adopted by consensus on 23.06.2022.

Opinion adopted on 23.06.2022.
Request for Supplementary Information adopted
on 31.03.2022.

Ziextenzo - pegfilgrastim - EMA/H/C/004802/II/0019	Positive Opinion adopted by consensus on 10.06.2022.
---	---

Sandoz GmbH, Rapporteur: Andrea Laslop
Opinion adopted on 10.06.2022.

WS2138/G Hexacima- EMA/H/C/002702/WS2138/0120/G Hexyon- EMA/H/C/002796/WS2138/0124/G	Request for supplementary information adopted with a specific timetable.
---	---

Sanofi Pasteur Europe, Duplicate, Duplicate of
Hexacima, Lead Rapporteur: Jan Mueller-
Berghaus
Request for Supplementary Information adopted
on 23.06.2022, 22.04.2022, 02.12.2021.

WS2193 Candidas- EMA/H/C/000379/WS2193/0075 Cubicin-EMA/H/C/000637/WS2193/0081 Invanz-EMA/H/C/000389/WS2193/0065 Ivemend- EMA/H/C/000743/WS2193/0046 Noxafil-EMA/H/C/000610/WS2193/0069 PREVYMIS- EMA/H/C/004536/WS2193/0025 Recarbrio- EMA/H/C/004808/WS2193/0013 Sivextro- EMA/H/C/002846/WS2193/0044 Temodal- EMA/H/C/000229/WS2193/0096 Zerbaxa- EMA/H/C/003772/WS2193/0037	Positive Opinion adopted by consensus on 02.06.2022.
--	---

Merck Sharp & Dohme B.V., Lead Rapporteur:
Filip Josephson
Opinion adopted on 02.06.2022.
Request for Supplementary Information adopted
on 31.03.2022.

WS2245 Hexacima- EMA/H/C/002702/WS2245/0129 Hexyon- EMA/H/C/002796/WS2245/0133	Positive Opinion adopted by consensus on 02.06.2022.
---	---

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-
Berghaus
Opinion adopted on 02.06.2022.

WS2258/G Infanrix hexa- EMA/H/C/000296/WS2258/0315/G GlaxoSmithKline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 23.06.2022.	Positive Opinion adopted by consensus on 23.06.2022.
---	---

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Avonex - interferon beta-1a - EMA/H/C/000102/II/0193 Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2 and 4.4 of the SmPC in order to update safety information for the paediatric population based on the final results of the Tecfidera Paediatric study (109MS306) (CONNECT - part 1), submitted as part of the PAM procedure P46/089, availability of data from published literature and post-marketing data from Biogen global safety database; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 16.06.2022.	Request for supplementary information adopted with a specific timetable.
Besremi - ropeginterferon alfa-2b - EMA/H/C/004128/II/0021 AOP Orphan Pharmaceuticals GmbH, Rapporteur: Janet Koenig, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on results from CONTINUATION-PV study. An open-label, multicentre, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with polycythaemia vera who previously participated in the PROUDPV study. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMA/H/C/002333/II/0112 GSK Vaccines S.r.l, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to add information based on Real World Evidence (RWE) on vaccination impact and effectiveness from literature references available up to July 2021. The MAH also proposes to remove the existing statement related to paediatric studies in section 5.1 of the SmPC. In addition, the MAH	Request for supplementary information adopted with a specific timetable.

took the opportunity to introduce minor editorial changes to the SmPC.”

Request for Supplementary Information adopted on 02.06.2022.

Biktarvy - bictegrovir / emtricitabine / tenofovir alafenamide -

EMA/H/C/004449/II/0047

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, “Update of sections 4.8 and 5.1 of the SmPC in order to include efficacy and safety data for antiretroviral therapy (ART)-naive adults based on final results from interventional studies GS-US-380-1489 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults) and GS-US-380-1490 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults).

In addition, the MAH took this opportunity to introduce some minor administrative updates.”
Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted on 05.05.2022.

Positive Opinion adopted by consensus on 10.06.2022.

Braftovi - encorafenib -
EMA/H/C/004580/II/0026

Pierre Fabre Medicament, Rapporteur: Janet Koenig, “Update of section 4.2 of the SmPC in order to introduce a new scheme of encorafenib dose reduction recommendations for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, by replacing the second dose reduction level of 200 mg once daily by 225 mg once daily; based on results from simulation report (ARRA-CSC-104). In addition, the MAH took the opportunity to introduce an update of the user instructions in the Package Leaflet for increased clarity.”

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 22.04.2022.

Positive Opinion adopted by consensus on 23.06.2022.

Cimzia - certolizumab pegol -

Positive Opinion adopted by consensus on

EMA/H/C/001037/II/0101 UCB Pharma S.A., Rapporteur: Kristina Dunder, "C.I.4: Update of section 4.6 of the SmPC in order to update information on pregnancy based on non-interventional data from the UCB Global Safety Database on prospective Cimzia-exposed pregnancies with known outcomes. The MAH also took the opportunity to make some minor updates in Annex IIIA and IIIB." Opinion adopted on 23.06.2022. Request for Supplementary Information adopted on 19.05.2022, 17.02.2022, 11.11.2021.	23.06.2022.
COMIRNATY - tozinameran - EMA/H/C/005735/II/0129 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8 and 5.1 of the SmPC of COMIRNATY 10 µg Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007 listed as a specific obligation in the Annex II; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information." Request for Supplementary Information adopted on 23.06.2022	Request for supplementary information adopted with a specific timetable. See 9.1
Cyramza - ramucirumab - EMA/H/C/002829/II/0043 Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on heart failure following a detailed cumulative review of post-marketing data. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the package leaflet to include hypothyroidism as a common side effect." Opinion adopted on 23.06.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 23.06.2022.

on 24.03.2022, 16.12.2021.

**Dapivirine Vaginal Ring 25 mg - dapivirine
- EMEA/H/W/002168/II/0014/G**

Positive Opinion adopted by consensus on
10.06.2022.

International Partnership for Microbicides
Belgium AISBL, Rapporteur: Paula Boudewina
van Hennik, "C.I.13: Submission of the study
report from study MTN-020 (Version 2.0). This
is a multicenter, randomized, double-blind,
placebo-controlled Phase III safety and
effectiveness trial of a vaginal matrix ring
containing dapivirine for the prevention of HIV-1
infection in women.

C.I.13: Submission of the Clinical Virology
Report (Version 4.0). This report describes
virologic characterisation of virus from HIV-1
seroconversion events during double-blind,
placebo-controlled, randomized, multicenter
Phase III clinical trials evaluating the safety and
efficacy of Dapivirine Vaginal Ring."

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted
on 24.03.2022, 13.01.2022.

**Darzalex - daratumumab -
EMA/H/C/004077/II/0060/G, Orphan**

Positive Opinion adopted by consensus on
02.06.2022.

Janssen-Cilag International N.V., Rapporteur:
Aaron Sosa Mejia, "C.I.4: Update of section 5.1
of the SmPC to include the final overall survival
(OS) results based on the final OS analysis for
pivotal study 54767414MMY3003 (MMY3003).
MMY3003 (Pollux) is an open-label, randomized,
active-controlled Phase III study that compared
treatment with DARZALEX 16mg/kg in
combination with lenalidomide (DRd) to
treatment with lenalidomide and low-dose
dexamethasone (Rd) in patients with relapsed
or refractory multiple myeloma who had
received at least one prior therapy.

C.I.4: Update of section 5.1 of the SmPC to
include the final overall survival (OS) results
based on the final OS analysis for pivotal studies
54767414MMY3004 (MMY3004). MMY3004
(Castor) is a Phase III, multicenter, randomized,
open-label, active-controlled study comparing
daratumumab in combination with bortezomib
and dexamethasone (DVd) with bortezomib and
dexamethasone (Vd) in subjects with relapsed
or refractory multiple myeloma.

In addition, the MAH took the opportunity to
implement some editorial changes."

Opinion adopted on 02.06.2022.

**Dovato - dolutegravir / lamivudine -
EMA/H/C/004909/II/0029**

Positive Opinion adopted by consensus on
10.06.2022.

ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC based on interim results from study 204862 (TANGO); this is an on-going 200-week, Phase III, randomized, open-label, active controlled, multicenter, parallel-group study, evaluating the efficacy, safety, and tolerability of switching to the Dovato fixed dose combination tablet (DTG/3TC FDC) in HIV-1 infected adults who are virologically suppressed.

In addition, the MAH took the opportunity to update sections 4.4 and 4.6 of the SmPC to delete the information related to sexual transmission and update of the text regarding HIV transmission in breastfeeding women following the CHMP recommendation in January 2022. The Package Leaflet is being updated accordingly.

In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

Opinion adopted on 10.06.2022.

**Dynastat - parecoxib -
EMA/H/C/000381/II/0085**

Positive Opinion adopted by consensus on
16.06.2022.

Pfizer Europe MA EEIG, Duplicate, Duplicate of Xapit (SRD), Rapporteur: Jayne Crowe, "Update of section 4.9 of the SmPC in order to amend it with the current medical guidance for acute NSAIDs poisoning/overdose. In addition, the MAH took the opportunity to introduce a minor editorial change to the PI and to update the list of local representatives in the Package Leaflet."

Opinion adopted on 16.06.2022.

**Evrenzo - roxadustat -
EMA/H/C/004871/II/0002**

Positive Opinion adopted by consensus on
23.06.2022.

Astellas Pharma Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add dermatitis exfoliative generalised (DEG) to the list of adverse drug reactions (ADRs) with frequency unknown based on post-marketing data and literature. In addition, the MAH took the opportunity to amend the Annex IIB in order to reflect the fact that restricted prescription applies.

Furthermore, the MAH took the opportunity to implement editorial changes to the SmPC.

The Package Leaflet was updated in line with the SmPC.
The requested variation proposed amendments to the Summary of Product Characteristics, Package Leaflet and Annex II.”
Opinion adopted on 23.06.2022.

**Eylea - aflibercept -
EMA/H/C/002392/II/0080**

Bayer AG, Rapporteur: Alexandre Moreau,
“Update of sections 4.2 and 5.1 of the SmPC in order to allow the individualisation of the treatment posology for intravitreal aflibercept in diabetic macular oedema (DME) indication based on a propensity-score-matching (PSM) analyses on patient-level-data comparison of the two pivotal studies in DME (VIVID & VISTA) versus the independently conducted Protocol T study as well as supporting data from a systematic literature review and confirmatory data from the recently completed VIOLET Phase 3b study. The Package Leaflet is updated accordingly.”
Request for Supplementary Information adopted on 23.06.2022.

Request for supplementary information adopted with a specific timetable.

**Fexinidazole Winthrop - fexinidazole -
EMA/H/W/002320/II/0010**

sanofi-aventis groupe, Rapporteur: Fátima Ventura, “Update of section 4.4 of the SmPC in order to add a new warning on severe irreversible hepatotoxicity in patients with Cockayne syndrome based on case reports and literature reviews; the Package Leaflet is updated accordingly.”
Opinion adopted on 23.06.2022.

Positive Opinion adopted by consensus on 23.06.2022.

**GONAL-f - follitropin alfa -
EMA/H/C/000071/II/0155**

Merck Europe B.V., Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.1, 4.2, 4.4, 5.1, 5.2 and 6.6 of the SmPC to revise the definition of severe LH and FSH deficiency, aligning with current medical guidelines and clinical practice, to clarify follicular development as the treatment target and selection of the most adequate Medically Assisted Reproduction procedure for healthcare providers, and the pharmacokinetic and pharmacodynamic properties of follitropin alfa; and to align with the Product Information of Pergoveris as previously assessed by the CHMP in procedure

Request for supplementary information adopted with a specific timetable.

EMA/H/C/000714/II/0075.

The package leaflet is updated accordingly. In addition, the applicant has taken the opportunity to improve the Instructions for Use (IFU) layout and to implement the Medical Device Regulation in the IFU."

Request for Supplementary Information adopted on 10.06.2022.

HBVAXPRO - hepatitis B vaccine (rDNA) - EMEA/H/C/000373/II/0076

Positive Opinion adopted by consensus on 02.06.2022.

Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller-Berghaus, "Update of section 5.1 of the SmPC in relation to study V419-013, following procedure EMEA/H/C/000373/P46/061. The sentence "As with other hepatitis B vaccines, the duration of the protective effect in healthy vaccinees is unknown at present" was revised to "The duration of the protective effect in healthy vaccinees is unknown".

In addition, the MAH took the opportunity to implement editorial changes in the SmPC, Labelling and the Package Leaflet."

Opinion adopted on 02.06.2022.

IBRANCE - palbociclib - EMEA/H/C/003853/II/0038/G

Request for supplementary information adopted with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, "C.I.4: Update of section 5.3 of the SmPC in order to update the primary target organ findings and development toxicity wording.

In addition, the MAH took the opportunity to update the list of local representatives (Belgium, Luxembourg, Germany and the Netherlands) in the Package Leaflet.

A.6: Update of Palbociclib ATC code based on the last revised classification of the Cyclin-dependent kinase (CDK) inhibitors made by the WHO."

Request for Supplementary Information adopted on 02.06.2022.

Imfinzi - durvalumab - EMEA/H/C/004771/II/0034

Positive Opinion adopted by consensus on 23.06.2022.

AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, "Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes. In

See 9.1

addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of the SmPC."

Opinion adopted on 23.06.2022. Request for Supplementary Information adopted on 22.04.2022, 20.01.2022, 21.10.2021.

INREBIC - fedratinib -

EMA/H/C/005026/II/0010/G, Orphan

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sonja Hrabcik, "Update of section 4.4 of the SmPC in order to add new warnings on major adverse cardiac events (MACE), thrombosis and secondary malignancies. The updates pertain to three signals, assessed by the FDA, which were identified with another JAK inhibitor (tofacitinib) indicated in rheumatoid arthritis; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Request for Supplementary Information adopted on 10.06.2022.

Request for supplementary information adopted with a specific timetable.

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein -
EMA/H/C/005737/II/0047/G

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Submission of the final reports from the non-clinical studies TV-TEC-207316, TV-TEC-207437, TOX15155, TV-TEC-215524 and TOX15252, listed as category 3 in the RMP. These are non-clinical studies conducted to further characterise the potential mechanisms underlying the important identified risks of thrombosis with thrombocytopenia syndrome (TTS) and thrombocytopenia, including immune thrombocytopenia (ITP)."
Request for Supplementary Information adopted on 23.06.2022.

Request for supplementary information adopted with a specific timetable.

Keytruda - pembrolizumab -
EMA/H/C/003820/II/0122

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning for 'Hypoparathyroidism' and to add it to the list of adverse drug reactions (ADRs) with frequency rare based on literature references; the Package Leaflet is updated accordingly."

Positive Opinion adopted by consensus on 16.06.2022.

Opinion adopted on 16.06.2022.

**Kineret - anakinra -
EMA/H/C/000363/II/0087**

Swedish Orphan Biovitrum AB (publ),
Rapporteur: Thalia Marie Estrup Blicher,
"C.I.13: Submission of the final report from
study SAVE-MORE, as requested as part of
procedure EMA/H/C/000363/II/086. This is a
prospective, double-blind, randomised, placebo-
controlled study to evaluate the efficacy and
safety of the early start of anakinra treatment
guided by suPAR in patients with LRTI by SARS-
CoV-2 in improving the clinical state of COVID-
19 patients over 28 days as measured by the
ordinal scale of the 11-point WHO-CPS.
Following review of the final CSR, the section
5.1 of the SmPC is updated to revise the
percentage of patients receiving dexamethasone
during treatment. The MAH also took the
opportunity to make some editorial changes in
the product information."

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted
on 22.04.2022.

Positive Opinion adopted by consensus on
10.06.2022.

**Kovaltry - octocog alfa -
EMA/H/C/003825/II/0038**

Bayer AG, Rapporteur: Kristina Dunder, PRAC
Rapporteur: Brigitte Keller-Stanislawski,
"Update of the SmPC sections 4.8 and 5.1 to
include data from the LEOPOLD Kids Part B
(previously submitted as Art 46; an addendum
on biomarker data is included in this
submission) and extension study results
included as part of this submission. In addition,
an editorial revision in section 4.2 and a
clarification in section 6.5 of the SmPC are
proposed. Section 4 of the Package Leaflet is
updated accordingly. A correction of a typo in
the Greek product information is also included.
The Risk Management Plan for Kovaltry is
updated using Revision 2.0.1 of the template
format."

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted
on 07.04.2022, 10.02.2022, 02.12.2021.

Positive Opinion adopted by consensus on
10.06.2022.

**Lokelma - sodium zirconium cyclosilicate -
EMA/H/C/004029/II/0025**

AstraZeneca AB, Rapporteur: Silvijus
Abramavicius, "Update of section 4.5 of the

Request for supplementary information adopted
with a specific timetable.

SmPC in order to add drug-drug interaction information based on final report for interventional study D9480C00012, "A Two-Cohort, Randomised Sequence, Crossover, Open-label Study to Assess the Effect of a Single Dose of Sodium Zirconium Cyclosilicate (SZC) on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects". The Package Leaflet is updated accordingly. In addition, MAH is taking this opportunity to update the contact details of the local representatives in the Package Leaflet." Request for Supplementary Information adopted on 10.06.2022.

**Lucentis - ranibizumab -
EMA/H/C/000715/II/0098**

Request for supplementary information adopted with a specific timetable.

Novartis Europharm Limited, Rapporteur: Kristina Dunder, "Update of section 4.6 of the SmPC in order to update information on breastfeeding following the PRAC Recommendation (EMA/H/C/PSUSA/00002609/202010) based on a cumulative assessment of pre-clinical studies, pharmacokinetic data, published literature and post-marketing spontaneous reports. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 02.06.2022.

**Luveris - lutropin alfa -
EMA/H/C/000292/II/0091**

Positive Opinion adopted by consensus on 23.06.2022.

Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.1, 4.2, 5.1 and 5.2 of the SmPC in order to update details regarding the definition of severe LH and FSH deficiency, to clarify follicular development as the treatment target and selection of the most adequate Medically Assisted Reproduction procedure for healthcare providers and to clarify the pharmacokinetic and pharmacodynamic properties of the two gonadotropins, in alignment with the variation EMA/H/C/000714/II/0075 for Pergoveris, based on a systematic literature search and review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 22.04.2022.

**Myozyme - alglucosidase alfa -
EMA/H/C/000636/II/0087**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to add palpitations, asthenia, malaise, feeling cold and blood pressure decreased to the list of adverse drug reactions (ADRs) with frequency "not-known" following the Final Assessment Report for the Post-Authorisation Measure MEAs 024.13 and 0.25.13 (the 2019 Pompe Disease Registry Annual Report) dated 15 October 2020; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 5.1 of the SmPC to update the internet website address of the Pompe Registry."

Request for Supplementary Information adopted on 10.06.2022, 07.04.2022, 20.01.2022.

Request for supplementary information adopted with a specific timetable.

**Neuraceq - florbetaben (18f) -
EMA/H/C/002553/II/0038**

Life Radiopharma Berlin GmbH, Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4 and 5.1 of the SmPC in order to include information on the possibility of quantitative assessment as an adjunct to visual read of Neuraceq scans based on final results from study titled "Evaluation of quantitative assessment of florbetaben (18F) PET scans as an adjunct to visual assessment". This is a retrospective data analysis to evaluate florbetaben PET quantification as an adjunct to the approved visual assessment method."

Request for Supplementary Information adopted on 16.06.2022.

Request for supplementary information adopted with a specific timetable.

**Onivyde pegylated liposomal - irinotecan
hydrochloride trihydrate -
EMA/H/C/004125/II/0031, Orphan**

Les Laboratoires Servier, Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC in order to update the duration of effective contraception in women with childbearing potential in line with the CHMP Safety working party (SWP) recommendations on the duration of contraception following the end of treatment with a genotoxic drug and to add a statement about the preservation of gametes. In addition, the MAH took the opportunity to introduce

Positive Opinion adopted by consensus on 10.06.2022.

minor changes to section 6.6 of the SmPC to provide clarification regarding the size of the needle to be used for the preparation of the infusion prior to administration. The Package Leaflet is updated accordingly.”

Opinion adopted on 10.06.2022.

**Onpattro - patisiran -
EMA/H/C/004699/II/0025, Orphan**

Alnylam Netherlands B.V., Rapporteur: Kristina Dunder, “Update of sections 4.2 and 5.1 of the SmPC based on interim results from study ALN-TTR02-006 listed as a category 3 study in the RMP; this is a multicenter, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial amyloidotic polyneuropathy who have completed a prior clinical study with patisiran.

In addition, the MAH took the opportunity to update section 3 of the SmPC in order to update the pH.”

Request for Supplementary Information adopted on 23.06.2022.

Request for supplementary information adopted with a specific timetable.

See 9.1

**Orladeyo - berotralstat -
EMA/H/C/005138/II/0006**

BioCryst Ireland Limited, Rapporteur: Peter Kiely, “Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 23.06.2022, 12.05.2022.

Request for supplementary information adopted with a specific timetable.

**Paxlovid - nirmatrelvir / ritonavir -
EMA/H/C/005973/II/0008**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Submission of the final report from study PMAR-EQDD-C467a-DP4-1323, listed as a legally binding measure. This is an updated population pharmacokinetics module results including PK data from the patients enrolled in the EPIC-HR study of Paxlovid.”

Request for Supplementary Information adopted on 16.06.2022.

Request for supplementary information adopted with a specific timetable.

Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0009 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.3 and 4.5 of the SmPC in order to remove piroxicam as a contraindicated medicinal product and to indicate that piroxicam exposure may be decreased due to interaction with Paxlovid, based on scientific literature. The package leaflet is updated accordingly." Opinion adopted on 23.06.2022.	Positive Opinion adopted by consensus on 23.06.2022.
Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0010/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC to add hypersensitivity to the list of adverse drug reactions with frequency common, based on a cumulative search of the MAH safety database; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to add drug-drug interaction information with dabigatran (P-gp substrate) based on the clinical study results from study C4671012, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of dabigatran; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to update the drug-drug interaction information of midazolam based on the clinical study results from study C4671013, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of midazolam. The MAH is taking the opportunity to include editorial updates in sections 4.3 and 6.1 of the SmPC." Request for Supplementary Information adopted on 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Prialt - ziconotide - EMEA/H/C/000551/II/0068 ESTEVE Pharmaceuticals GmbH, Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to adjust the posology regimen. Update of sections 4.2, 4.3, 4.4 and 4.8 to add information regarding the increased risk of suicide. Update of section 5.1 to add a paragraph regarding responsive daily dose. The Package Leaflet to be updated accordingly. In addition, the MAH took the opportunity to update QRD template to v.10.2 Rev.1 and	Positive Opinion adopted by consensus on 23.06.2022. See 9.1

implement editorial changes in SmPC, PL, and Labelling.”
Opinion adopted on 23.06.2022.
Request for Supplementary Information adopted on 22.04.2022, 27.01.2022, 16.09.2021.

**REKAMBYS - rilpivirine -
EMA/H/C/005060/II/0008**

Request for supplementary information adopted with a specific timetable.

Janssen-Cilag International N.V., Rapporteur:
Johann Lodewijk Hillege, “Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on week 96 results from the clinical study 207966 (ATLAS-2M). This is a open-label, randomized, Phase IIIb trial to demonstrate non-inferior antiviral activity and safety of CAB + RPV Q8W compared with CAB + RPV Q4W. Supporting Cabotegravir (CAB) Long-acting Injectable (LA) + Rilpivirine (RPV) LA every 2 months (Q8W) dosing regimen for the treatment of HIV-1 infection.”
Request for Supplementary Information adopted on 23.06.2022, 16.12.2021.

**RINVOQ - upadacitinib -
EMA/H/C/004760/II/0019**

Positive Opinion adopted by consensus on 02.06.2022.

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Kristina Dunder, “Update of section 4.5 of the SmPC in order to add information about drug interaction with grapefruit as a CYP3A4 inhibitor based on literature references; the Package Leaflet is updated accordingly.”
Opinion adopted on 02.06.2022.

**Roclanda - latanoprost / netarsudil -
EMA/H/C/005107/II/0002**

Positive Opinion adopted by consensus on 02.06.2022.

Santen Oy, Rapporteur: Jayne Crowe, “C.I.4, Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study PG324-CS303; this is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of Roclanda compared to bimatoprost + timolol in subjects with elevated intraocular pressure that was insufficiently controlled and/or deemed to be in need of combination IOP-lowering therapy. The Package Leaflet is updated accordingly.”
Opinion adopted on 02.06.2022.
Request for Supplementary Information adopted on 24.02.2022.

Rozlytrek - entrectinib - EMA/H/C/004936/II/0010 Roche Registration GmbH, Rapporteur: Armando Genazzani, "Submission of the final report from study (RO7102122) to address the non-clinical recommendation issued within the initial MAA. This is an in-vitro study for the evaluation of entrectinib against novel clinically-relevant NTRK fusions using the Ba/F3 cell line." Opinion adopted on 02.06.2022.	Positive Opinion adopted by consensus on 02.06.2022.
Rybelsus - semaglutide - EMA/H/C/004953/II/0025 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'Hypersensitivity' to the list of adverse drug reactions (ADRs) with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 23.06.2022.	Positive Opinion adopted by consensus on 23.06.2022.
SARCLISA - isatuximab - EMA/H/C/004977/II/0014 sanofi-aventis groupe, Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on Infections by adding herpes zoster prophylaxis as antiviral prophylaxis, following FDA post-market survey and request to update the US PI based on a cumulative assessment of Sanofi global PV database and scientific literature. The Package Leaflet is updated accordingly." Opinion adopted on 02.06.2022.	Positive Opinion adopted by consensus on 02.06.2022.
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMA/H/C/004336/II/0054 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Update of section 4.5 of the SmPC based on final results from study ZOSTER-059; this is a Phase IIIB, open label, randomised, controlled study to evaluate the immunogenicity, safety and reactogenicity of Shingrix when co-administered with Prevenar 13 in adults ≥ 50 years of age. In addition, the MAH took the opportunity to update section 4.5 of the SmPC to update the existing statement to specify the incidence percentages of fever and shivering upon co-	Request for supplementary information adopted with a specific timetable.

administration of Shingrix with PPV23 based on study ZOSTER-035.”

Request for Supplementary Information adopted on 23.06.2022.

**Somavert - pegvisomant -
EMA/H/C/000409/II/0102**

Positive Opinion adopted by consensus on 16.06.2022.

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Update of section 5.1 of the SmPC in order to include details on insulin sensitivity based on the results of the ACROSTUDY (A6291010) and additional literature. In addition, the MAH took the opportunity to introduce editorial changes to the list of local representatives in the Package Leaflet.”

Opinion adopted on 16.06.2022.

Request for Supplementary Information adopted on 07.04.2022.

**SonoVue - sulphur hexafluoride -
EMA/H/C/000303/II/0049**

Request for supplementary information adopted with a specific timetable.

Bracco International B.V., Rapporteur:

Alexandre Moreau, “Update of sections 4.1, 4.4 and 5.1 of the SmPC based on final results from study BR1-145 listed as a PAES in the Annex II; this is an observational, retrospective, multicentre, comparative study conducted in patients below 18 years of age who had undergone a VUS exam with intravesically administered SonoVue/Lumason or a VCUG exam as part of their standard of care for evaluation of known or suspected VUR.”

Request for Supplementary Information adopted on 23.06.2022.

**Toviaz - fesoterodine -
EMA/H/C/000723/II/0063**

Request for supplementary information adopted with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Maria

Concepcion Prieto Yerro, “C.I.3

Update of sections 4.2, 5.1 and 5.2 of the SmPC with the results from study A0221047, to evaluate the safety and efficacy of fesoterodine in subjects aged 6 to 17 years with neurogenic detrusor overactivity. The change was suggested in the outcome of the EMA/H/C/000723/P46/030.1.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1.”

Request for Supplementary Information adopted

on 23.06.2022, 03.03.2022, 14.10.2021.

Trecondi - treosulfan -

EMA/H/C/004751/II/0016, Orphan

medac Gesellschaft für klinische

Spezialpräparate mbH, Rapporteur: Fátima Ventura, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 23.06.2022.

Request for supplementary information adopted with a specific timetable.

TRODELVY - sacituzumab govitecan -

EMA/H/C/005182/II/0008

Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from the repeat-dose toxicity study (3277-001) with the novel excipient 2-(N-morpholino) ethane sulfonic acid (MES). This is a non-clinical toxicology study titled "A 1-Month Study of MES by Intravenous Injection in Sprague Dawley Rats with a 1- and a 7-Day Post Dose Observation Periods"."

Opinion adopted on 16.06.2022.

Positive Opinion adopted by consensus on 16.06.2022.

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) -

EMA/H/C/004051/II/0037

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC in order to include immunopersistence and booster data based on final results from study B1971035 listed as a part of the paediatric investigation plan; this is a phase 2, randomized, controlled, observer-blinded study conducted to describe the immunogenicity, safety, and tolerability of Bivalent rLP2086 when administered to healthy toddlers aged 12 to <18 months or 18 to <24 months, and the safety and immunogenicity of a booster dose of Bivalent rLP2086."

Request for Supplementary Information adopted on 16.06.2022, 17.02.2022.

Request for supplementary information adopted with a specific timetable.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

EMA/H/C/005675/II/0031

AstraZeneca AB, Rapporteur: Sol Ruiz,
"Submission of the final study report for MS1222-0002 "In Vitro Assay to Determine Release of Spike Protein From Transduced Cells" to fulfil the imposed study as reflected in Annex II of the product information and the RMP. As a result, Annex II of the product information is being updated to remove this study.

The MAH is taking the opportunity to provide two additional studies linked to support the investigation on the platelet activation: the final study report for MS1222-0001 "Computational Prediction of Spike Protein Interaction with Platelet Factor 4 (PF4)" which is the first report requested within the required studies for "in vitro interaction of AZD1222 or spike protein with PF4 and/or platelets" as reflected in the RMP; and the study report for 520447 "Investigative Vaccine Study in the Mouse" to evaluate spike protein levels and haematology parameters."

Request for Supplementary Information adopted on 23.06.2022, 13.01.2022, 23.09.2021.

Request for supplementary information adopted with a specific timetable.

Veklury - remdesivir -

EMA/H/C/005622/II/0036

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of sections 4.4 and 5.1 of the SmPC in order to update information regarding the baseline serostatus of patients included in the study GS US 540 9012 (Phase 3, randomized, double blind, placebo controlled study to evaluate RDV treatment of COVID 19 in an outpatient setting) listed as a Recommendation (number 24) within the procedure EMA/ 005622/II/0016 that led to the extension of indication of remdesivir to adults with confirmed COVID 19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease."

Opinion adopted on 16.06.2022.

Positive Opinion adopted by consensus on 16.06.2022.

Veklury - remdesivir -

EMA/H/C/005622/II/0037/G

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped variations to update sections 4.5, 5.2 and 6.6 of the SmPC to update prescribing information related to interactions

Request for supplementary information adopted with a specific timetable.

with other medicinal products, effect of intrinsic factors and COVID-19 disease on the pharmacokinetics (PK) of Veklury and its metabolites in the adult population. Data from the Phase 1 drug-drug interaction (DDI) study GS US 540 9013, adult COVID-19 participant PK data collected across two Phase 3 studies (GS-US-540-9012 and CO-US-540-5844), and an exposure-safety analysis are included in addition to nonclinical in vitro drug metabolism studies to complete the metabolism profiling. This variation is submitted to cover Recommendations 9,11,12 and 13 listed at the time of the conditional marketing authorisation (EMA/H/C/005622/0000) for Veklury. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some linguistic amendments.”

Request for Supplementary Information adopted on 23.06.2022.

**VITRAKVI - larotrectinib -
EMA/H/C/004919/II/0021**

Positive Opinion adopted by consensus on 10.06.2022.

Bayer AG, Rapporteur: Filip Josephson, “Update of section 5.2 of the SmPC in order to reflect the outcome of an updated analysis of the population pharmacokinetic (PopPk) model based on additional PK sampling in patients aged 1 month to 6 years from study LOXO-TRK-15003 (SCOUT) imposed as a specific obligation (SOB). The MAH is also proposing to delete this SOB from Annex II. The MAH took the opportunity of this variation to introduce corrections to section 4.8 of the SmPC and to Annex II. In addition, the MAH corrected the name of a local representative in the PL.”

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted on 17.03.2022, 02.12.2021.

**Vocabria - cabotegravir -
EMA/H/C/004976/II/0008**

Request for supplementary information adopted with a specific timetable.

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, “Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on week 96 results from the clinical study 207966 (ATLAS-2M). This is an open-label, randomized, Phase IIIb trial to demonstrate non-inferior antiviral activity and safety of CAB + RPV Q8W compared with CAB +

RPV Q4W. Supporting Cabotegravir (CAB) Long-acting Injectable (LA) + Rilpivirine (RPV) LA every 2 months (Q8W) dosing regimen for the treatment of HIV-1 infection.”

Request for Supplementary Information adopted on 23.06.2022, 16.12.2021.

**Vyepti - eptinezumab -
EMA/H/C/005287/II/0001**

Positive Opinion adopted by consensus on 16.06.2022.

H. Lundbeck A/S, Rapporteur: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC in order to add infusion-related reaction to the list of adverse drug reactions (ADRs) with frequency common, and to update the frequency of anaphylactic reaction to uncommon (from rare) based on a signal assessment conducted by the MAH. The Package Leaflet is updated accordingly.”

Opinion adopted on 16.06.2022.

**Wegovy - semaglutide -
EMA/H/C/005422/II/0003/G**

Request for supplementary information adopted with a specific timetable.

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, “Update of section 5.1 of the SmPC in order to update the description of the pharmacodynamic effects and clinical efficacy and safety based on final results from interventional studies: Trial 4378 (STEP 5) which compared the two-year effect of semaglutide 2.4 mg once weekly versus placebo; Trial 4576 (STEP 8) which compared semaglutide s.c. 2.4 mg once weekly to liraglutide s.c. 3.0 mg once daily and Trial 4373 extension (STEP 1ext) which explored the change in body weight, cardiovascular risk factors and glucose metabolism in subjects who completed 68 weeks of treatment (semaglutide 2.4 mg or placebo) followed by a 52-week off-treatment period.”

Request for Supplementary Information adopted on 02.06.2022.

**Xarelto - rivaroxaban -
EMA/H/C/000944/II/0093**

Positive Opinion adopted by consensus on 16.06.2022.

Bayer AG, Rapporteur: Kristina Dunder, “Update of section 5.1 and subsequent changes in sections 4.2 and 4.8 based on final results from study 18226 (UNIVERSE); this is a prospective, open-label, active controlled, multicenter, 2-part study, designed to evaluate the single- and multiple-dose pharmacokinetic properties of rivaroxaban (Part A), and to evaluate the safety

and efficacy of rivaroxaban when used for thromboprophylaxis for 12 months compared with acetylsalicylic acid (Part B) in children 2 to 8 years of age with single ventricle physiology who had the Fontan procedure.

In addition, the MAH took the opportunity to introduce editorial changes to sections 4.8 and 4.9 of the SmPC."

Opinion adopted on 16.06.2022.

Request for Supplementary Information adopted on 24.03.2022.

WS2224

Eucreas-

EMA/H/C/000807/WS2224/0094

Galvus-EMA/H/C/000771/WS2224/0075

Icandra-

EMA/H/C/001050/WS2224/0097

Jalra-EMA/H/C/001048/WS2224/0077

Xiliarx-EMA/H/C/001051/WS2224/0075

Zomarist-

EMA/H/C/001049/WS2224/0096

Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to update the list of ADRs and update the ADR table in line with the EC SmPC guideline (2009). The Package Leaflet is updated accordingly."

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 17.03.2022.

WS2241/G

Advagraf-

EMA/H/C/000712/WS2241/0065/G

Modigraf-

EMA/H/C/000954/WS2241/0039/G

Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, "Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on the adverse reaction Thrombotic microangiopathy (TMA) based on a cumulative review of fatal cases of TMA during treatment with tacrolimus, requested by the PRAC following the assessment of the PSUR (EMA/H/C/00002839/202103).

Update of section 4.5 of the SmPC in order to add the drug-drug interaction between tacrolimus and caspofungin based on post-marketing safety report and literature.

Update of section 5.2 of the SmPC in order to

Positive Opinion adopted by consensus on 23.06.2022.

Request for supplementary information adopted with a specific timetable.

add that tacrolimus is metabolised by the cytochrome P450-3A5 (CYP3A5) based on post-marketing safety report and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement some editorial changes.” Request for Supplementary Information adopted on 10.06.2022.

WS2244

Nuwiq-EMA/H/C/002813/WS2244/0048
Vihuma-

EMA/H/C/004459/WS2244/0030

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing of the sentence “A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing” in section 5.1 of the SmPC. The Package Leaflet is updated accordingly.” Request for Supplementary Information adopted on 16.06.2022, 05.05.2022.

Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

Afstyla - lonoctocog alfa -
EMA/H/C/004075/II/0042

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik, “Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 3001 listed as a category 3 study in the RMP; this is an open label, multicenter extension study to assess the Safety and Efficacy of Afstyla in subjects with severe Hemophilia A. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 6.0 has also been submitted.” Opinion adopted on 10.06.2022.

Positive Opinion adopted by consensus on 10.06.2022.

Request for Supplementary Information adopted on 10.03.2022.

**Alecensa - alectinib -
EMA/H/C/004164/II/0037/G**

Positive Opinion adopted by consensus on 23.06.2022.

Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add a new warning, dose modification advice and description of the known ADR haemolytic anaemia based on an updated Drug Safety Report; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial updates in the English, Maltese, Romanian, French, Swedish and Italian product information. Moreover, the ATC code for alectinib is being updated from L01XE36 to L01ED03."

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 19.05.2022, 27.01.2022.

**Cablivi - caplacizumab -
EMA/H/C/004426/II/0035, Orphan**

Positive Opinion adopted by consensus on 10.06.2022.

Ablynx NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on increased risk of bleeding and add blood and lymphatic system disorders to the list of adverse drug reactions (ADRs) with frequency not known based on a safety evaluation report; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted on 07.04.2022, 13.01.2022.

**Carbaglu - carglumic acid -
EMA/H/C/000461/II/0044**

Request for supplementary information adopted with a specific timetable.

Recordati Rare Diseases, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of sections 4.2 and 4.4 of the SmPC in order to include information on the impact of renal impairment on systemic exposures to Carbaglu following a FDA request, based on final results from study A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Carbaglu in Subjects with Normal and Varying Degrees of Impaired Renal Function."

See 9.1

The Package Leaflet is updated accordingly.
The RMP version 2.2 has also been submitted.
In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Request for Supplementary Information adopted on 23.06.2022.

Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0016

Positive Opinion adopted by consensus on 23.06.2022.

International Partnership for Microbicides
Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Jan Neuhauser, “Update of the Annex II for Dapivirine in order to replace the current PAES: Phase IV, open label, multicentre efficacy trial in healthy HIV-negative young women age 18-25 years (IPM 055), listed as a category 1 study in the RMP, with the implementation study: Dapivirine vaginal ring implementation in a real-world setting in young women. An updated RMP version 0.9 was submitted as part of the application.”

See 9.1

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 07.04.2022.

ELZONRIS - tagraxofusp - EMEA/H/C/005031/II/0009, Orphan

Positive Opinion adopted by consensus on 23.06.2022.

Stemline Therapeutics B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.4 and 5.3 of the SmPC to reflect safety information from the final report from study 20255431 (CRL-263114) 'Characterization of fixed choroid plexus samples from primate study MPI-2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The updated RMP version 2.2 has also been submitted.”

See 9.1

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 22.04.2022, 13.01.2022.

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0047, Orphan

Request for supplementary information adopted with a specific timetable.

Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Annika Folin, “Submission of the final report from study BO21223/GALLIUM listed as a category 3 study

in the RMP. This is an open-label, international, multicenter, randomized, Phase III study to investigate the efficacy and safety of obinutuzumab administration at standard infusion rate plus chemotherapy followed by obinutuzumab maintenance therapy for responders (G-chemo arm) compared with rituximab plus chemotherapy followed by rituximab maintenance therapy for responders (R-chemo arm) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (iNHL). The RMP version 9.0 has also been submitted."

Request for Supplementary Information adopted on 10.06.2022.

IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0059, Orphan

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update information and amend the frequencies of adverse drug reactions (ADRs) based on the final results from study CSL654_3003 listed as a category 3 study in the RMP; this is an open-label, multicentre, uncontrolled study to evaluate the safety, pharmacokinetics and clinical response of rIX-FP with regard to the prevention and treatment of bleeding in previously untreated patients (PUPs) with Haemophilia B. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 10.06.2022.

Request for supplementary information adopted with a specific timetable.

Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0024, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from clinical study VX17-445-105 (study 105) listed as a category 3 study in the RMP; this is a Phase III, open label extension study to evaluate the long-term safety and efficacy of

Request for supplementary information adopted with a specific timetable.

ELX/TEZ/IVA in CF subjects homozygous for F508del (F/F genotype) or heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

The RMP version 6.1 has also been submitted.

In addition, the MAH took the opportunity to implement minor corrections (section 5.3 and 6.5) as well as editorial changes to the SmPC.

The requested variation proposed amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP)."

Request for Supplementary Information adopted on 10.06.2022.

Kisqali - ribociclib -

EMA/H/C/004213/II/0035

Positive Opinion adopted by consensus on 10.06.2022.

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final Overall Survival (OS) analysis from study A2301 (MONALEESA-2); a Phase III, randomized, double-blind, placebo-controlled, multicenter study of ribociclib in combination with letrozole in postmenopausal women with HR+, HER2-, locoregionally recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease, and based on an updated pooled safety dataset (including the studies MONALEESA-2, MONALEESA-3 and MONALEESA-7). The Package Leaflet was updated accordingly.

The study is listed as a category 3 study in the RMP, and the submission of the final study report addresses MEA 004. An updated RMP version 6.0 was also submitted."

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted on 07.04.2022.

Mylotarg - gemtuzumab ozogamicin -

EMA/H/C/004204/II/0024, Orphan

Positive Opinion adopted by consensus on 23.06.2022.

Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on the final results from study B176103; this is a single-arm, open-label, phase 4 study evaluating the QT interval, pharmacokinetics, and safety of gemtuzumab ozogamicin as a single-agent regimen in patients with relapsed or refractory

CD33-positive Acute Myeloid Leukaemia. The RMP version 2.2 has also been submitted. In addition, the MAH took the opportunity to introduce some editorial changes in the product information."

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 19.05.2022, 18.03.2022.

**Neofordex - dexamethasone -
EMA/H/C/004071/II/0017/G**

Positive Opinion adopted by consensus on 23.06.2022.

Laboratoires CTRS, Rapporteur: Ondřej Slanař, PRAC Rapporteur: Tiphaine Vaillant"1. C.I.11.z (Type IB): To update the RMP for Neofordex to version 4.3 with a completion of category 3 activity 'Removal of the score line for sub-division of the 40 mg tablet, and consequent deletion of the 20 mg posology' and to include the Direct Healthcare Professional Communication (DHPC)."

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 05.05.2022.

**Nerlynx - neratinib -
EMA/H/C/004030/II/0027**

Positive Opinion adopted by consensus on 23.06.2022.

Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Menno van der Elst, "Submission of the final results from study PUMA-NER-6201 (CONTROL), listed as a category 3 study in the RMP; this is an Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide. The RMP version 3.0 has also been submitted."

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 10.02.2022.

**Opsumit - macitentan -
EMA/H/C/002697/II/0046, Orphan**

Positive Opinion adopted by consensus on 10.06.2022.

Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "Update of sections 4.6 and 5.3 of the SmPC in order to introduce additional data on male fertility based on literature search and global safety database. The RMP version 13.1 has also been submitted."

Opinion adopted on 10.06.2022.

Oxlumo - lumasiran -

Request for supplementary information adopted

EMA/H/C/005040/II/0008, Orphan

Alnylam Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to clarify administration instructions, remove an existing warning on metabolic acidosis in patients with severe or end stage renal impairment, update the description of adverse reactions injection site reactions, abdominal pain and immunogenicity, update efficacy, pharmacokinetic information based on interim results from a category 3 study in the RMP ILLUMINATE-C (ALN-GO1-005): A single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) and, in addition, based on available long-term efficacy and safety data from ongoing phase 3 studies ALN-GO1-003 in PH1 patients >6 years old and ALN-GO1-004 in PH1 patients <6 years old, and open-label extension study ALN-GO1-002. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted."

Request for Supplementary Information adopted on 23.06.2022, 24.02.2022.

with a specific timetable.

Paxlovid - nirmatrelvir / ritonavir - EMA/H/C/005973/II/0007

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Submission of the final report from study C4671010 listed as a category 3 study in the RMP. This is a phase I, non-randomized, open label study to assess the pharmacokinetics, safety and tolerability of PF-07321332 boosted with ritonavir in adults with moderate hepatic impairment and individuals with normal hepatic function. The RMP version 2.0 has also been submitted."

Request for Supplementary Information adopted on 10.06.2022.

Request for supplementary information adopted with a specific timetable.

Replagal - agalsidase alfa - EMA/H/C/000369/II/0117

Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.2 and 6.6 of the SmPC in order to add self-administration by a trained patient and/or a caregiver as a new

Request for supplementary information adopted with a specific timetable.

method of administration. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. The RMP version 0.1 has also been submitted.”

Request for Supplementary Information adopted on 23.06.2022, 24.03.2022.

**RINVOQ - upadacitinib -
EMA/H/C/004760/II/0015/G**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Kristina Dunder, PRAC Rapporteur:
Nikica Mirošević Skvrce, “Grouping of 2
variations:

C.I.4 - Update of sections 4.8 to add neutropenia and 5.1 of the SmPC in order to update efficacy information of Rinvoq in Ankylosing Spondylitis (AS) patients who are biologic DMARD inadequate responders (bDMARD-IR) based on interim results from study M19-944 study 1; this is a Phase 3, randomized, double-blind, study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with active AS who have an inadequate response (IR) to bDMARD.

C.I.4 - Update of section 5.1 of the SmPC in order to include long-term (through week 104) data in AS patients who are naïve to previous treatment with a bDMARD based on interim results from study M16-098; this is a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis;
The RMP version 7.0 is adopted.

In addition, the MAH took the opportunity to introduce minor editorial changes in the product information.

The recommendation on the present application is without prejudice to the final conclusions of the ongoing referral procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data.”

Opinion adopted on 23.06.2022.

Request for Supplementary Information adopted on 24.03.2022.

Positive Opinion adopted by consensus on 23.06.2022.

**RINVOQ - upadacitinib -
EMA/H/C/004760/II/0020/G**

AbbVie Deutschland GmbH & Co. KG,

Request for supplementary information adopted with a specific timetable.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Hypersensitivity' and add it to the list of adverse drug reactions (ADRs) with frequency not known. The MAH also proposed to update section 4.8 of the SmPC in order to add 'Non-Melanoma Skin Cancer (NMSC)' to the list of adverse drug reactions (ADRs) with frequency uncommon. The Package Leaflet has been updated accordingly. The RMP version 9.0 has also been submitted."

Request for Supplementary Information adopted on 10.06.2022.

**Scintimun - besilesomab -
EMA/H/C/001045/II/0015**

CIS BIO International, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, "Submission of the final report from the clinical study AG-2012 - Non interventional controlled survey on the impact of Scintimun administered for scintigraphic imaging on diagnostic thinking and management of patient with suspicion of peripheral osteomyelitis, listed as a category 3 study in the RMP - MEA 08.4. An updated RMP version 15 was submitted."

Request for Supplementary Information adopted on 10.06.2022.

Request for supplementary information adopted with a specific timetable.

**Spikevax - elasomeran -
EMA/H/C/005791/II/0062**

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Submission of an updated RMP version 4.0 in order to remove 'anaphylaxis' as an important identified risk; to remove 'interaction with other vaccines' as a safety concern in study mRNA-1273-P904 following the outcome of the EMA/H/C/005791/MEA/004.4 procedure; to implement the WHO-approved INN 'elasomeran'; to update the study milestones for the mRNA-1273-P301, mRNA1273-P203, mRNA-1273-P201, mRNA-1273-P901, mRNA-1273-P903 and mRNA-1273-P910 studies and to add study mRNA-1273-P911 to the RMP. The Annex II of the Product Information is updated accordingly.

The requested variation proposed amendments

Positive Opinion adopted by consensus on 23.06.2022.

to the Annex II and to the Risk Management Plan (RMP)."

Opinion adopted on 23.06.2022.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -

EMA/H/C/005675/II/0075

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.1 of the SmPC in order to include updated efficacy information based on the 6 months follow-up analysis from study D8110C00001 listed as a specific obligation in the Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria. The RMP version 5.1 has also been submitted. The MAH removed the important identified risk of anaphylaxis from the list of safety concerns, updated the routine and additional pharmacovigilance activities section and took the opportunity to implement other administrative updates."

Request for Supplementary Information adopted on 23.06.2022.

Request for supplementary information adopted with a specific timetable.

Vemlidy - tenofovir alafenamide -

EMA/H/C/004169/II/0038

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Amelia Cupelli, "Submission of the final week 192 report from study GS-US-320-3912; 'A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF)-containing Regimens in Subjects with Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant', listed as a category 3 study in the RMP. The RMP version 8.1 has also been submitted."

Request for Supplementary Information adopted on 10.06.2022.

Request for supplementary information adopted with a specific timetable.

B.5.4. PRAC assessed procedures

PRAC Led

HEPLISAV B - hepatitis b surface antigen -
EMA/H/C/005063/II/0015

Dynavax GmbH, PRAC Rapporteur: Brigitte

Request for supplementary information adopted with a specific timetable.

Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from the study HBV-26: Post-Marketing Observational Surveillance Study to Evaluate the Incidence of New-Onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis, listed as a category 3 post-authorisation safety study (PASS) in the RMP.

This is a post-marketing observational surveillance study comparing the incidence of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in recipients of HEPLISAV B with recipients of another hepatitis B vaccine. The RMP version 1.3 has also been submitted."

Request for Supplementary Information adopted on 10.06.2022.

PRAC Led

Jinarc - tolvaptan -

EMA/H/C/002788/II/0036

Otsuka Pharmaceutical Netherlands B.V., PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of an updated RMP version 15.0 in order to reflect the outcome of the substantial amendment to the protocol of the category 1 PASS study (156-12-299) as concluded in (PSA/S/0078.1). The Annex II is updated accordingly. In addition, the MAH took the opportunity to correct an oversight/editorial error in the Package Leaflet relevant to (II/0033/G)."

Request for Supplementary Information adopted on 10.06.2022.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Mysimba - naltrexone hydrochloride / bupropion hydrochloride -

EMA/H/C/003687/II/0054

Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of the final report from study NB-542 listed as a category 3 PASS in the RMP. This is a cross-sectional survey aimed to evaluate the effectiveness of the Mysimba Physician Prescribing Checklist (PPC) among physicians in the EU. The RMP version 12.6 has also been submitted."

Request for Supplementary Information adopted on 10.06.2022, 10.02.2022.

Request for supplementary information adopted with a specific timetable.

PRAC Led Praluent - alirocumab - EMA/H/C/003882/II/0068 sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC, based on the final results from category 3 study OBS14697; a non-interventional, retrospective drug utilisation study that was designed to assess in Europe the effectiveness of the dosing recommendation and to describe patterns of alirocumab utilisation in real world clinical practice. In addition, the MAH took the opportunity to implement editorial changes in SmPC and package leaflet. The submission of the study report addresses the Post-Authorisation Measure EMA/FSR 019.8." Opinion adopted on 10.06.2022. Request for Supplementary Information adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.06.2022.
PRAC Led Rotarix - rotavirus vaccine (live, oral) - EMA/H/C/000639/II/0125 GlaxoSmithKline Biologicals S.A., PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study EPI-ROTA-052 BOD EU SUPP (201433) listed as a category 3 study in the RMP. This is an observational community-based strain surveillance study to monitor the potential emergence and spread of novel RV strains throughout Europe. RMP version 23 has been approved with this procedure." Opinion adopted on 10.06.2022.	Positive Opinion adopted by consensus on 10.06.2022.
PRAC Led Stelara - ustekinumab - EMA/H/C/000958/II/0091 Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final safety registry report of CNT01275PSO4007 "Pregnancy Research Initiative: Exposure to ustekinumab during pregnancy: A review and analysis of birth outcomes from the Swedish, Danish and Finnish medical birth registers." Consequently, the RMP version 22.1 has been updated."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 10.06.2022, 10.02.2022.

PRAC Led	Positive Opinion adopted by consensus on 10.06.2022.
----------	--

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) -

EMA/H/C/004051/II/0040

Pfizer Europe MA EEIG, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from PASS B1971052 - A Pregnancy and Birth Outcome Assessment in a Population-based Cohort After Exposure to Trumenba, listed as a category 3 study in the RMP (MEA 001).

Study B1971052 is a population-based, non-interventional cohort study utilising administrative healthcare claims data."

Opinion adopted on 10.06.2022.

PRAC Led	Request for supplementary information adopted with a specific timetable.
----------	--

VIZAMYL - flutemetamol (18F) -

EMA/H/C/002557/II/0029

GE Healthcare AS, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study (GE067-027) listed as a category 3 study in the RMP in addition to a comprehensive root-cause analysis on the contributing factors having an impact on reader performance as requested by PRAC. This is a non-interventional post-authorisation safety study (PASS) to evaluate the effectiveness of VIZAMYL reader training in Europe. The RMP version 3.1 has also been submitted and updated to reflect the completion of study GE067-028, previously assessed in MEA 003.3."

Request for Supplementary Information adopted on 10.06.2022.

PRAC Led	Positive Opinion adopted by consensus on 10.06.2022.
----------	--

XALKORI - crizotinib -

EMA/H/C/002489/II/0075

Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report for non-interventional PASS cat 3 study A8081062, a descriptive study of potential sight threatening event and severe visual loss following exposure to crizotinib (related to MEA 024). The RMP version 7.5 has also been submitted."

Opinion adopted on 10.06.2022.
Request for Supplementary Information adopted
on 10.03.2022.

PRAC Led Xeljanz - tofacitinib - EMA/H/C/004214/II/0044 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "C.I.3.b - Update of sections 4.4, 4.8 and 5.1 to add warnings and safety data on serious infections, viral reactivation, non-melanoma skin cancer and fractures. This is based on the final results from study A3921133 listed as a category 3 study in the RMP; this is a post-authorisation safety study conducted to evaluate the safety of tofacitinib 5 mg and 10 mg compared to TNFi in adults' subjects aged ≥50 years with moderately or severely active RA and with at least 1 additional CV risk factor. The Package Leaflet is updated accordingly. The RMP version 21.1 has also been submitted. In addition, the MAH took the opportunity to update the outer carton (section 4 for oral solution) to include a total volume of 240 mL as requested following the completion of the procedure EMA/H/C/004214/X/0024/G." Opinion adopted on 10.06.2022. Request for Supplementary Information adopted on 07.04.2022, 02.12.2021.	Positive Opinion adopted by consensus on 10.06.2022.
---	---

PRAC Led WS2191 Incesync- EMA/H/C/002178/WS2191/0040 Vipdomet- EMA/H/C/002654/WS2191/0036 Vipidia-EMA/H/C/002182/WS2191/0029 Takeda Pharma A/S, Lead PRAC Rapporteur: Menno van der Elst, "Submission of a consolidated RMP version 11 for Vipidia, Vipdomet and Incesync in order to: - Update the RMPs for Alogliptin, Alogliptin/Pioglitazone fixed dose combination (FDC) and Alogliptin/Metformin fixed dose combination (FDC) to consolidate within a single RMP as committed within the PSUR procedure (PSUSA/00010061/202104). - Following review of cumulative safety data, removal of a number of safety concerns is done	Positive Opinion adopted by consensus on 10.06.2022.
---	---

based on GVP Module V, Risk Management Systems (revision 2) guidelines.

- Remove the target follow-up Questionnaires of Severe Hypersensitivity and skin reactions, Pancreatitis, Hepatic events and follow up gastrointestinal events and infections from Alogliptin and Alo/Met RMPs.
- Reflect the removal of the inverted black triangle as agreed as part of the alogliptin renewal procedure (EMA/H/C/002178/R/0023) for Alogliptin and the FDC Alogliptin/Metformin. The black triangle was already removed from the FDC Alogliptin/Pioglitazone RMP as part of the Type II variation (EMA/H/C/002178/II/0029)."

Opinion adopted on 10.06.2022.
Request for Supplementary Information adopted on 10.02.2022.

PRAC Led	Positive Opinion adopted by consensus on
WS2196	10.06.2022.

Glyxambi-
EMA/H/C/003833/WS2196/0042
Jardiance-
EMA/H/C/002677/WS2196/0063
Synjardy-
EMA/H/C/003770/WS2196/0060

Boehringer Ingelheim International GmbH, Lead PRAC Rapporteur: Eva A. Segovia, "Submission of the results from the final meta-analysis report of PASS 1245.171 'A meta-analysis of amputation risk in empagliflozin studies (1245.25, 1245.110, 1245.121)' (included as a category 3 study in the RMP). Updated RMP versions have also been submitted to add the ongoing study EMPA-KIDNEY (1245.137) in the Pharmacovigilance Plan as additional pharmacovigilance activity to address the safety concern 'amputation risk' and to add other minor updates; version 18.1 for Jardiance, version 12.1 for Synjardy and version 7.1 for Glyxambi."

Opinion adopted on 10.06.2022.
Request for Supplementary Information adopted on 10.02.2022.

PRAC Led	Positive Opinion adopted by consensus on
WS2261	10.06.2022.

Lyrica-EMA/H/C/000546/WS2261/0118
Pregabalin Pfizer-
EMA/H/C/003880/WS2261/0047

Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To update SmPC sections 4.4 and 4.8 with a warning regarding severe cutaneous adverse reactions (SJS and TEN); the PL was updated accordingly."
Opinion adopted on 10.06.2022.

PRAC Led
WS2268
Dovato-EMA/H/C/004909/WS2268/0031
Juluca-EMA/H/C/004427/WS2268/0044
Tivicay-EMA/H/C/002753/WS2268/0079
Triumeq-
EMA/H/C/002754/WS2268/0104

Request for supplementary information adopted with a specific timetable.

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "To update section 4.8 of the SmPC and section 4 of the PL to include the ADR "weight increased" with a frequency "common".
In addition, the marketing authorisation holder has taken the opportunity to implement a minor editorial change in the German SmPC for Juluca."
Request for Supplementary Information adopted on 10.06.2022.

B.5.5. CHMP-CAT assessed procedures

Imlygic - talimogene laherparepvec - EMA/H/C/002771/II/0052/G, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuori,
Opinion adopted on 23.06.2022, 17.06.2022.
Request for Supplementary Information adopted on 13.05.2022.

Positive Opinion adopted by consensus on 23.06.2022.

Kymriah - tisagenlecleucel - EMA/H/C/004090/II/0055, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang
Request for Supplementary Information adopted on 17.06.2022.

Request for supplementary information adopted with a specific timetable.

Kymriah - tisagenlecleucel - EMA/H/C/004090/II/0056, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune

Request for supplementary information adopted with a specific timetable.

Kjeken, CHMP Coordinator: Ingrid Wang,
"Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information in paediatric population based on study CCTLO19C2202, a phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in paediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA).
The Package Leaflet is updated accordingly."
Request for Supplementary Information adopted on 17.06.2022.

WS2269
Tecartus-
EMA/H/C/005102/WS2269/0022
Yescarta-
EMA/H/C/004480/WS2269/0051

Positive Opinion adopted by consensus on 23.06.2022.

Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Opinion adopted on 23.06.2022.

B.5.6. CHMP-PRAC-CAT assessed procedures

Tecartus - brexucabtagene autoleucel -
EMA/H/C/005102/II/0019, Orphan,
ATMP

Positive Opinion adopted by consensus on 23.06.2022.

Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information based on 24-month follow-up data from all treated patients in cohort 1 of the pivotal clinical study, KTE-C19-102 (ZUMA-2); a Phase 2, multicenter, open-label study evaluating the safety and efficacy of KTE-X19 in subjects with relapsed or refractory (r/r) mantle cell lymphoma (MCL). This submission is in fulfilment of the specific obligation (SOB 004) to confirm the long-term efficacy and safety of Tecartus in adult patients with relapsed/refractory (r/r) MCL. As a consequence, Annex II E has been updated with deletion of the fulfilled SOB. In addition, the MAH has taken the opportunity to make minor editorial changes in the SmPC. The RMP version 2.1 has also been submitted."

Opinion adopted on 23.06.2022, 17.06.2022.

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2227 Esperoct- EMA/H/C/004883/WS2227/0011 NovoEight- EMA/H/C/002719/WS2227/0040 Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.06.2022. Request for Supplementary Information adopted on 28.04.2022.	Positive Opinion adopted by consensus on 02.06.2022.
---	---

WS2234/G Ebymect- EMA/H/C/004162/WS2234/0055/G Edistride- EMA/H/C/004161/WS2234/0052/G Forxiga- EMA/H/C/002322/WS2234/0073/G Qtern- EMA/H/C/004057/WS2234/0034/G Xigduo- EMA/H/C/002672/WS2234/0065/G AstraZeneca AB, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 02.06.2022. Request for Supplementary Information adopted on 22.04.2022.	Positive Opinion adopted by consensus on 02.06.2022.
--	---

WS2236/G Aflunov- EMA/H/C/002094/WS2236/0077/G Foclivia- EMA/H/C/001208/WS2236/0075/G Seqirus S.r.l, Lead Rapporteur: Armando Genazzani Opinion adopted on 02.06.2022. Request for Supplementary Information adopted on 22.04.2022.	Positive Opinion adopted by consensus on 02.06.2022.
---	---

WS2242 Mircera-EMA/H/C/000739/WS2242/0090 NeoRecormon- EMA/H/C/000116/WS2242/0117 Roche Registration GmbH, Lead Rapporteur: Martina Weise	Positive Opinion adopted by consensus on 02.06.2022.
--	---

Opinion adopted on 02.06.2022.

WS2248/G

Aflunov-

EMA/H/C/002094/WS2248/0078/G

Foclivia-

EMA/H/C/001208/WS2248/0076/G

Seqirus S.r.l, Lead Rapporteur: Armando
Genazzani

Opinion adopted on 10.06.2022.

Request for Supplementary Information adopted
on 22.04.2022.

Positive Opinion adopted by consensus on
10.06.2022.

WS2256/G

Copalia-

EMA/H/C/000774/WS2256/0124/G

Copalia HCT-

EMA/H/C/001159/WS2256/0099/G

Dafiro-

EMA/H/C/000776/WS2256/0128/G

Dafiro HCT-

EMA/H/C/001160/WS2256/0101/G

Exforge-

EMA/H/C/000716/WS2256/0123/G

Exforge HCT-

EMA/H/C/001068/WS2256/0098/G

Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher
Opinion adopted on 02.06.2022.

Positive Opinion adopted by consensus on
02.06.2022.

WS2262

Hexacima-

EMA/H/C/002702/WS2262/0130

Hexyon-

EMA/H/C/002796/WS2262/0134

Sanofi Pasteur Europe, Duplicate, Duplicate of
Hexacima, Lead Rapporteur: Jan Mueller-
Berghaus

Opinion adopted on 23.06.2022.

Positive Opinion adopted by consensus on
23.06.2022.

WS2266

Blitzima-

EMA/H/C/004723/WS2266/0056

Truxima-

EMA/H/C/004112/WS2266/0059

Celltrion Healthcare Hungary Kft., Lead
Rapporteur: Sol Ruiz

Opinion adopted on 02.06.2022.

Positive Opinion adopted by consensus on
02.06.2022.

WS2267/G

CoAprovel-

EMA/H/C/000222/WS2267/0210/G

Karvezide-

Positive Opinion adopted by consensus on
16.06.2022.

EMA/H/C/000221/WS2267/0210/G

sanofi-aventis groupe, Duplicate, Duplicate of
Karvezide, Lead Rapporteur: Maria Concepcion
Prieto Yerro
Opinion adopted on 16.06.2022.

WS2278/G**Copalia-****EMA/H/C/000774/WS2278/0125/G****Copalia HCT-****EMA/H/C/001159/WS2278/0100/G****Dafiro-****EMA/H/C/000776/WS2278/0129/G****Dafiro HCT-****EMA/H/C/001160/WS2278/0102/G****Exforge-****EMA/H/C/000716/WS2278/0124/G****Exforge HCT-****EMA/H/C/001068/WS2278/0099/G**

Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher
Request for Supplementary Information adopted
on 23.06.2022.

Request for supplementary information adopted
with a specific timetable.

WS2284**Edistride-****EMA/H/C/004161/WS2284/0054****Forxiga-****EMA/H/C/002322/WS2284/0075**

AstraZeneca AB, Lead Rapporteur: Kristina
Dunder, "To reflect the compliance with the
agreed completed paediatric investigation plan
PIP/0086/20202 as adopted by PDCO in
November 2021."
Opinion adopted on 23.06.2022.

Positive Opinion adopted by consensus on
23.06.2022.

B.5.9. Information on withdrawn type II variation / WS procedure

Remicade - infliximab -**EMA/H/C/000240/II/0235**

Janssen Biologics B.V., Rapporteur: Kristina
Dunder, "Update of section 4.8 of the SmPC in
order to add 'Orbital Apex Syndrome' to the list
of adverse drug reactions (ADRs) with frequency
very rare based on a cumulative review and
literature references; the Package Leaflet is
updated accordingly. In addition, the MAH took
the opportunity to introduce minor editorial
changes to the PI according to the QRD
template version 10.2 rev.1."
Withdrawal request submitted on 02.06.2022.

The MAH withdrew the procedure on
02.06.2022.

**Trogarzo - ibalizumab -
EMA/H/C/004961/II/0018**

Theratechnologies Europe Limited, Rapporteur:
Johann Lodewijk Hillege, "Update of section 5.1
of the SmPC in order to add additional efficacy
data based on results from study TMB-311, a
multicenter, expanded access phase 3 study
providing post-hoc long-term data on patients
from study TMB-301."

Request for Supplementary Information adopted
on 24.03.2022.

The MAH withdrew the procedure on
16.06.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

**Myozyme - alglucosidase alfa -
EMA/H/C/000636/II/0090**

Genzyme Europe BV, Rapporteur: Alexandre
Moreau, PRAC Rapporteur: Nathalie Gault, ,
"Submission of the final report from non-
interventional PASS Pompe Safety Sub-Registry
- AGLU06909/LTS13930. This final study report
is submitted to address the assessment report
conclusion of the Pompe registry report 2020
(MEA024.15 and MEA025.15 Annual Pompe
Registry Report 2020)."

Request for Supplementary Information adopted
on 05.05.2022.

Request by the applicant for an extension to the
clock stop to respond to the RSI adopted in May
2022.

The CHMP agreed to the request by the
applicant.

**Spikevax - elasomeran -
EMA/H/C/005791/II/0057**

Moderna Biotech Spain, S.L., Rapporteur: Jan
Mueller-Berghaus, "Update of section 4.2 of the
Spikevax SmPC to include a 50 µg booster dose
for adolescents 12 to 18 years of age, based on
the extrapolation of safety and efficacy data
from young adults (18 to 24 years of age). The
package leaflet is updated accordingly."

Request for Supplementary Information adopted
on 22.04.2022.

Request by the applicant for an extension to the
clock stop to respond to the RSI adopted in April
2022. The clock stop extension was adopted via
written procedure on 03 June 2022.

Action: For information

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION**B.6.1. Start of procedure for New Applications: timetables for information**

aripiprazole - EMA/H/C/005929

Maintenance treatment of schizophrenia

crisantaspase - EMA/H/C/005917

Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).

pirtobrutinib - EMEA/H/C/005863, Orphan

Eli Lilly Nederland B.V., treatment of mantle cell lymphoma (MCL)

treprostinil diolamine -

EMEA/H/C/005990, Orphan

Ferrer Internacional S.A., Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.

gentamicin sulfate / sargramostim /

heparin sodium / insulin human -

EMEA/H/D/006090

human assisted reproductive techniques including in-vitro fertilisation procedures

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Hefiya - adalimumab -

EMEA/H/C/004865/X/0036/G

Sandoz GmbH, Duplicate, Duplicate of Hyrimoz, Rapporteur: Daniela Philadelphia, PRAC
Rapporteur: Ulla Wändel Liminga, "Extension application to add a new strength (80 mg/0.8 ml) of the solution for injection grouped with quality variations. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 9.0) has also been submitted. Additionally, the applicant takes the opportunity to include editorial changes in the pack sizes in the List of All Authorised Presentations (Annex A).

Hyrimoz - adalimumab -

EMEA/H/C/004320/X/0036/G

Sandoz GmbH, Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to add a new strength (80 mg/0.8 ml) of the solution for injection grouped with quality variations. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 9.0) has also been submitted. Additionally, the applicant takes the opportunity to include editorial changes in the pack sizes in the List of All Authorised Presentations (Annex

A).

**Orkambi - lumacaftor / ivacaftor -
EMA/H/C/003954/X/0078/G**

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Armando Genazzani, PRAC
Rapporteur: Rhea Fitzgerald, "Extension
application to add a new strength of 75 mg of
lumacaftor and 94 mg of ivacaftor fixed dose
combination granules, grouped with a type II
variation (C.I.6.a).

C.I.6: Extension of indication to include
treatment of cystic fibrosis for children aged 1
to less than 2 years old of age who are
homozygous for the F508del mutation in the
CFTR gene, based on final results from study
122, a 2-part study of CF subjects 1 to <2 years
of age homozygous for F508del. As a
consequence, sections 4.1, 4.2, 4.5, 4.6, 4.8,
5.1 and 5.2 of the SmPC are updated. The
Package Leaflet is updated in accordance.
Version 11.2 of the RMP has also been
submitted."

**B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables:
for information**

nirsevimab - EMA/H/C/005304

prevention of RSV lower respiratory tract
infection.

Immunise infants from birth entering their first
Respiratory Syncytial Virus (RSV) season for the
prevention of RSV lower respiratory tract
disease

List of Questions adopted on 17.05.2022.

mavacamten - EMA/H/C/005457

treatment of symptomatic obstructive
hypertrophic cardiomyopathy

List of Questions adopted on 27.01.2022.

Dupixent - dupilumab -

EMA/H/C/004390/X/0057

sanofi-aventis groupe, Rapporteur: Jan Mueller-
Berghaus

List of Questions adopted on 22.04.2022.

gozetotide - EMA/H/C/005488

indicated for the identification of prostate-
specific membrane antigen (PSMA)-positive
lesions after radiolabelling with gallium-68

List of Questions adopted on 24.02.2022.

**lutetium (177Lu) vipivotide tetraxetan -
EMA/H/C/005483**

treatment of prostate-specific membrane
antigen (PSMA)-positive metastatic castration-
resistant prostate cancer (mCRPC)

List of Questions adopted on 24.02.2022.

**in vitro diagnostic medical device -
EMA/H/D/006078**

detection of PD-L1 protein

Request for Supplementary Information adopted
on 19.05.2022, 22.04.2022.

plerixafor - EMA/H/C/005943

treatment of lymphoma and multiple myeloma

List of Questions adopted on 24.02.2022.

**efbemalenograstim alfa -
EMA/H/C/005828**

Reduction in the duration of neutropenia and
the incidence of febrile neutropenia.

List of Questions adopted on 27.01.2022.

**Skyrizi - risankizumab -
EMA/H/C/004759/X/0020/G**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Peter Kiely, PRAC Rapporteur:
Liana Gross-Martirosyan, "Extension application
to:

- introduce a new pharmaceutical form
(concentrate for solution for infusion), a new
strength (600 mg) and a new route of
administration (intravenous use).

- add a new strength of 360 mg (150 mg/ml)
for risankizumab solution for injection (in
cartridge) for subcutaneous use.

The above new presentations are indicated for
the treatment of patients 16 years and older
with moderately to severely active Crohn's
disease who have had an inadequate response
to, lost response to, or were intolerant to
conventional therapy or a biologic therapy, or if
such therapies are not advisable.

The RMP (version 4.0) is updated in
accordance."

List of Questions adopted on 22.04.2022.

spesolimab - EMA/H/C/005874

treatment of flares in adult patients with
generalised pustular psoriasis

List of Questions adopted on 24.02.2022.

teclistamab - EMEA/H/C/005865, Orphan

Janssen-Cilag International N.V., treatment of
relapsed or refractory multiple myeloma
List of Questions adopted on 17.05.2022.

teriflunomide - EMEA/H/C/005960

treatment of multiple sclerosis (MS)
List of Questions adopted on 24.02.2022.

deucravacitinib - EMEA/H/C/005755

treatment of moderate to severe plaque
psoriasis in adults who are candidates for
systemic therapy
List of Questions adopted on 24.02.2022.

loncastuximab tesirine -**EMEA/H/C/005685, Orphan**

FGK Representative Service GmbH, treatment of
adult patients with relapsed or refractory large
B-cell lymphoma
List of Questions adopted on 24.02.2022.

B.6.4. Annual Re-assessments: timetables for adoption

EVKEEZA - evinacumab -**EMEA/H/C/005449/S/0005**

Ultragenyx Germany GmbH, Rapporteur:
Johann Lodewijk Hillege, PRAC Rapporteur:
Annika Folin

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Alofisel - darvadstrocel -**EMEA/H/C/004258/R/0036, Orphan,
ATMP**

Takeda Pharma A/S, Rapporteur: Lisbeth
Barkholt, Co-Rapporteur: Margarida Menezes-
Ferreira, CHMP Coordinators: Kristina Dunder
and Fátima Ventura, PRAC Rapporteur: Brigitte
Keller-Stanislawski

Anagrelide Mylan - anagrelide -**EMEA/H/C/004585/R/0010**

Mylan Pharmaceuticals Limited, Generic,
Generic of Xagrid, Rapporteur: Alar Irs, PRAC
Rapporteur: Tiphaine Vaillant

Darunavir Krka - darunavir -**EMEA/H/C/004273/R/0013**

KRKA, d.d., Novo mesto, Generic, Generic of
Prezista, Rapporteur: John Joseph Borg, PRAC

Rapporteur: Liana Gross-Martirosyan

**Efavirenz/Emtricitabine/Tenofovir
disoproxil Krka - efavirenz / emtricitabine
/ tenofovir disoproxil -
EMA/H/C/004274/R/0015**

KRKA, d.d., Novo mesto, Generic, Generic of
Atripla (SRD), Rapporteur: John Joseph Borg,
PRAC Rapporteur: Martin Huber

**Fulvestrant Mylan - fulvestrant -
EMA/H/C/004649/R/0016**

Mylan Pharmaceuticals Limited, Generic,
Generic of Faslodex, Rapporteur: Elita
Poplavska, PRAC Rapporteur: Annika Folin

**GAVRETO - pralsetinib -
EMA/H/C/005413/R/0006**

Roche Registration GmbH, Rapporteur: Aaron
Sosa Mejia, PRAC Rapporteur: Annika Folin

**Herzuma - trastuzumab -
EMA/H/C/002575/R/0050**

Celltrion Healthcare Hungary Kft., Rapporteur:
Jan Mueller-Berghaus, Co-Rapporteur: Outi
Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-
Stanislowski

**Mylotarg - gemtuzumab ozogamicin -
EMA/H/C/004204/R/0025, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa
Mejia, Co-Rapporteur: Alexandre Moreau, PRAC
Rapporteur: Marcia Sofia Sanches de Castro
Lopes Silva

**NINLARO - ixazomib -
EMA/H/C/003844/R/0040, Orphan**

Takeda Pharma A/S, Rapporteur: Armando
Genazzani, Co-Rapporteur: Filip Josephson,
PRAC Rapporteur: Annika Folin

**Ocaliva - obeticholic acid -
EMA/H/C/004093/R/0034, Orphan**

Intercept Pharma International Limited,
Rapporteur: Blanca Garcia-Ochoa, Co-
Rapporteur: Armando Genazzani, PRAC
Rapporteur: Liana Gross-Martirosyan

**RYBREVA - amivantamab -
EMA/H/C/005454/R/0002**

Janssen-Cilag International N.V., Rapporteur:
Filip Josephson, PRAC Rapporteur: Brigitte
Keller-Stanislowski

Segluromet - ertugliflozin / metformin

hydrochloride -

EMA/H/C/004314/R/0015

Merck Sharp & Dohme B.V., Rapporteur:
Kristina Dunder, Co-Rapporteur: Agnes
Gyurasics, PRAC Rapporteur: Menno van der
Elst

Steglatro - ertugliflozin -

EMA/H/C/004315/R/0015

Merck Sharp & Dohme B.V., Rapporteur:
Kristina Dunder, Co-Rapporteur: Agnes
Gyurasics, PRAC Rapporteur: Menno van der
Elst

Steglujan - ertugliflozin / sitagliptin -

EMA/H/C/004313/R/0018

Merck Sharp & Dohme B.V., Rapporteur:
Kristina Dunder, Co-Rapporteur: Agnes
Gyurasics, PRAC Rapporteur: Menno van der
Elst

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Breyanzi - lisocabtagene maraleucel /

lisocabtagene maraleucel -

EMA/H/C/004731/II/0005, ATMP

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Concetta Quintarelli, CHMP Coordinator:
Armando Genazzani, PRAC Rapporteur: Brigitte
Keller-Stanislawski, "Extension of indication to
include treatment of adult patients with Second-
line (2L) Transplant Intended (TI) Large B-Cell
Lymphoma (LBCL) for BREYANZI, based on
interim analyses from pivotal study JCAR017-
BCM-003; this is a global randomized
multicentre Phase III Trial to compare the
efficacy and safety of JCAR017 to standard of
care in adult subjects with high-risk, transplant-
eligible relapsed or refractory aggressive B-cell
Non-Hodgkin Lymphomas (TRANSFORM); As a
consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2
of the SmPC are updated. The Package Leaflet is
updated in accordance. Version 2.0 of the RMP
has also been submitted."

Cosentyx - secukinumab -

EMA/H/C/003729/II/0090

Novartis Europharm Limited, Rapporteur: Outi

Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia, "Extension of indication to include treatment of Hidradenitis Suppurativa (HS) for COSENTYX, based on interim results from two Phase III studies CAIN457M2301 (SUNSHINE) and CAIN457M2302 (SUNRISE); These studies are ongoing, multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 3 studies conducted to assess the short (16 weeks) and long-term (up to 52 weeks) efficacy and safety of two secukinumab dose regimens (Q2W or Q4W) compared to placebo in adult subjects with moderate to severe HS; As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2. of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted."

**Enhertu - trastuzumab deruxtecan -
EMA/H/C/005124/II/0022**

Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy; for ENHERTU, based on final results from study DS8201-A-U303 (DESTINY-Breast04). This is a Phase III, multicentre, randomised, open-label, active-controlled trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus treatment of physician's choice for HER2-low, unresectable and/or metastatic breast cancer subjects.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.4 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update section 4.4 of the SmPC to update the dosing recommendation for corticosteroid treatment

(e.g. prednisolone) with a daily dose.”

Epidyolex - cannabidiol -

EMA/H/C/004675/II/0020, Orphan

GW Pharma (International) B.V., Rapporteur:

Thalia Marie Estrup Blicher, Co-Rapporteur:

Ondřej Slanař, PRAC Rapporteur: Ana Sofia

Diniz Martins, “Extension of indication to include

treatment with Epidyolex (monotherapy) as

adjunctive therapy of seizures associated with

Lennox Gastaut syndrome (LGS) or Dravet

syndrome (DS) for patients 2 years of age and

older (without the restriction for use only in

conjunction with clobazam), based on the

previously generated data in patients treated

without CLB in the LGS and DS pivotal studies

re-evaluated in the context of the more recent

evidence from study GWEP1521 in tuberous

sclerosis complex (TSC). As a consequence,

sections 4.1, 4.5, 4.8, 5.1, 5.2 and 5.3 of the

SmPC are updated. The Package Leaflet is

updated in accordance. In addition, the MAH

took the opportunity to implement editorial

changes in the product information. Version 2.1

of the RMP has also been submitted.”

EVUSHELD - tixagevimab / cilgavimab -

See 5.1

EMA/H/C/005788/II/0001

AstraZeneca AB, Rapporteur: Jan Mueller-

Berghaus, Co-Rapporteur: Christophe Focke,

PRAC Rapporteur: Kimmo Jaakkola, “Extension

of indication to include treatment of adults and

adolescents (aged 12 years and older weighing

at least 40 kg) with COVID-19, who do not

require supplemental oxygen, based on interim

results from study D8851C00001 (TACKLE); this

is an ongoing, randomized, double-blind,

placebo-controlled, multicenter study assessing

the safety and efficacy of a single 600 mg dose

of AZD7442 (× 2 IM injections) compared with

matching placebo for the treatment of mild to

moderate COVID-19 in non-hospitalized adults.

As a consequence, sections 4.1, 4.2, 4.8, 4.9,

5.1, 5.2 and 6.6 of the SmPC are updated. The

Package Leaflet and Labelling are updated in

accordance. Version 2 succession 1 of the RMP

has also been submitted.”

Mircera - methoxy polyethylene glycol-

epoetin beta - EMA/H/C/000739/II/0092

Roche Registration GmbH, Rapporteur: Maria

Concepcion Prieto Yerro, “Extension of indication

to include treatment of paediatric patients from 3 months to less than 18 years of age requiring dialysis or not yet on dialysis and switching from another ESA to Mircera, based on final results from study NH19708; this is a single-arm, open-label, Phase II study of Mircera in patients aged 3 months to <18 years with CKD on dialysis or not yet on dialysis to generate PK, efficacy, and safety data for subcutaneous (SC) administration of Mircera. In addition, supportive data from studies NH19707, Modelling & Simulation study (study 3) and MH40258 were included. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instruction for Use in the Package Leaflet.”

Spikevax - elasomeran -

See 5.1

EMA/H/C/005791/II/0067

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Marie Louise Schougaard Christiansen, “Extension of indication to include immunisation of paediatric individuals from 6 months through 5 years of age based on results from the study P204 (KidCove); this is a phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. The MAH also took the opportunity to implement minor editorial changes in the product information.

The submission includes a revised RMP version 4.1.”

TachoSil - human thrombin / human

fibrinogen - EMA/H/C/000505/II/0117

Corza Medical GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Extension of indication to include treatment of children aged 1 month to 18 years,

based on available bibliographical data, results from study TC-2402-040-SP which compared TachoSil with Surgicel Original as adjunct to primary surgical treatment in both adult and paediatric subjects, and results from study TC-019-IN; a prospective, uncontrolled study in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the product information. Version 0.1 of the RMP has also been submitted.”

**Vemlidy - tenofovir alafenamide -
EMA/H/C/004169/II/0040**

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Amelia Cupelli, “Extension of indication to include treatment of chronic hepatitis B-infected children from 6 years and older and weighing at least 25 kilograms for Vemlidy, based on the interim results from Week 24 clinical study report (CSR) for Cohort 1 and Cohort 2 Group 1 and supporting modular summaries for the category 3 study GS-US-320-1092, ‘A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection’. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.

In addition, the MAH took the opportunity to update the wording in section 4.6 of the SmPC related to breastfeeding and pregnancies exposed to TAF, and to update the contact details of the local representative in Romania in the Package Leaflet.

An updated RMP version 8.2 has been provided.”

**Wakix - pitolisant -
EMA/H/C/002616/II/0030, Orphan**

Bioprojet Pharma, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka, “Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years, based on results from study P11-06; an

ongoing phase III, double-blind, multicentre, randomized, placebo-controlled trial undertaken to evaluate safety and efficacy of pitolisant in children from 6 to less than 18 years with narcolepsy with/without cataplexy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted.”

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

COMIRNATY - tozinameran - EMA/H/C/005735/II/0130/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
--	-----------

COMIRNATY - tozinameran - EMA/H/C/005735/II/0131 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
--	-----------

COMIRNATY - tozinameran - EMA/H/C/005735/II/0134/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
--	--

COMIRNATY - tozinameran - EMA/H/C/005735/II/0135/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
--	--

COMIRNATY - tozinameran - EMA/H/C/005735/II/0136 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
--	--

Entyvio - vedolizumab - EMA/H/C/002782/II/0070/G Takeda Pharma A/S, Rapporteur: Armando Genazzani	
--	--

Erelzi - etanercept - EMA/H/C/004192/II/0040/G Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege	
--	--

Erelzi - etanercept - EMA/H/C/004192/II/0042/G Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege	
--	--

**EVUSHELD - tixagevimab / cilgavimab -
EMA/H/C/005788/II/0002/G**

AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus

**Firazy - icatibant -
EMA/H/C/000899/II/0054/G, Orphan**

Takeda Pharmaceuticals International AG,
Rapporteur: Kristina Dunder

**Flud Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) -
EMA/H/C/004993/II/0030**

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMA/H/C/004814/II/0027

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

**Fluenz Tetra - influenza vaccine (live attenuated, nasal) -
EMA/H/C/002617/II/0117**

AstraZeneca AB, Rapporteur: Christophe Focke

**IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) -
EMA/H/C/002596/II/0075/G**

Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus

**Increlex - mecasermin -
EMA/H/C/000704/II/0077/G**

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola

**Kadcyla - trastuzumab emtansine -
EMA/H/C/002389/II/0066/G**

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher

**OXERVATE - cenegermin -
EMA/H/C/004209/II/0038/G, Orphan**

Dompe farmaceutici S.p.A., Rapporteur: Maria Concepcion Prieto Yerro

**Padcev - enfortumab vedotin -
EMA/H/C/005392/II/0001**

Astellas Pharma Europe B.V., Rapporteur: Aaron Sosa Mejia

**Rekovelte - follitropin delta -
EMA/H/C/003994/II/0034**

Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race

Rhokiinsa - netarsudil -**EMA/H/C/004583/II/0010/G**

Santen Oy, Rapporteur: Jayne Crowe

Sogroya - somapacitan -**EMA/H/C/005030/II/0004/G, Orphan**

Novo Nordisk A/S, Rapporteur: Johann Lodewijk

Hillege

VPRIV - velaglucerase alfa -**EMA/H/C/001249/II/0055, Orphan**

Takeda Pharmaceuticals International AG,

Rapporteur: Martina Weise

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

COMIRNATY - tozinameran -

See B.5.2 and 9.1

EMA/H/C/005735/II/0129

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8 and 5.1 of the SmPC of COMIRNATY 10 µg Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007 listed as a specific obligation in the Annex II; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information."

Dificlir - fidaxomicin -**EMA/H/C/002087/II/0049**

Tillotts Pharma GmbH, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC in order to introduce a new posology regimen based on final results from EXTEND study - A Phase IIIb/IV Randomized, Controlled, Open-Label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium difficile Infection in an Older Population. The Package Leaflet is updated accordingly."

**Enhertu - trastuzumab deruxtecan -
EMA/H/C/005124/II/0019**

Daiichi Sankyo Europe GmbH, Rapporteur:
Aaron Sosa Mejia, "Update of section 4.2 of the SmPC to add nausea/vomiting premedication prophylaxis information following procedure II/14 based on analyses from study DS8201-A-U302 (DESTINY-Breast03); this is a Phase 3, multicenter, randomized, open-label, 2-arm, active controlled study in subjects with unresectable and/or metastatic HER2-positive breast cancer previously treated with trastuzumab and a taxane. The Package Leaflet is updated accordingly."

**Esperoct - turoctocog alfa pegol -
EMA/H/C/004883/II/0013, Orphan**

Novo Nordisk A/S, Rapporteur: Andrea Laslop,
"Update of section 4.2 of the SmPC in order to delete the statement in reference to previously untreated patients (PUPs) and section 5.1 of the SmPC in order to update information based on final results from study NN7088-3908; this is an open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of turoctocog alfa pegol (N8-GP) in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

**Imbruvica - ibrutinib -
EMA/H/C/003791/II/0074**

Janssen-Cilag International N.V., Rapporteur:
Filip Josephson, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the information related to Paediatrics following assessment done in procedure P46/035, based on results from the paediatric study LYM3003 "A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Paediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma".
The Package Leaflet is updated accordingly."

**Imbruvica - ibrutinib -
EMA/H/C/003791/II/0075**

Janssen-Cilag International N.V., Rapporteur:
Filip Josephson, "Update of section 4.2 of the SmPC to incorporate information specific for dose modifications for non-cardiac events and

events of cardiac failure or cardiac arrhythmias events based on data pool from clinical studies which included 4 Phase II (PCYC-1102-CA, PCYC-1104-CA, PCYC-1118E, PCYC-1142-CA) and 8 Phase III studies (PCYC-1112-CA, PCYC-1115-CA, CLL3001, PCYC-1130-CA, MCL3001, PCYC-1127-CA, CLL3011, and MCL3002)."

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0053/G

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to introduce an heterologous booster dose of JCOVDEN following priming with another adenoviral vector-based vaccine and an inactivated whole virion COVID-19 vaccine based on literature evidence from studies COV-BOOST and RHH-01 respectively. Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of JCOVDEN as homologous and heterologous booster dose based on data from studies COV2008, a randomised, double-blind Phase 2 study and literature evidence from studies COV-BOOST, RHH-001 and DMID 21-0012. The Package Leaflet is updated accordingly."

Koselugo - selumetinib - EMEA/H/C/005244/II/0006/G, Orphan

AstraZeneca AB, Rapporteur: Alexandre Moreau, "Submission of the reports for the long-term efficacy and safety updates from study D1532C00057: SPRINT Phase I and SPRINT Phase II Stratum 1 to fulfil the Specific Obligations SOB/003 and SOB/002, respectively, listed in the Annex II of the Product Information. This is a phase I/II study of the mitogen activated protein kinase kinase (MEK) 1 inhibitor selumetinib (AZD6244; HYD-Sulfate) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)."

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0011/G

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, "Grouped variation: - C.I.4 (Type II): Update of section 5.1 of the SmPC in order to introduce data on clinical

efficacy against the Omicron variant of concern, based on data from study 2019nCoV-101 (Parts 1 and 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and published literature. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information.

- C.I.13 (Type II): Submission of the final clinical report from study 2019nCoV-101 (Part 1), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988).

This submission addresses the post-authorisation measures MEA 009, REC 041 and REC 042."

**Oncaspar - pegaspargase -
EMA/H/C/003789/II/0048**

Les Laboratoires Servier, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 4.4 of the SmPC in order to add advice on premedication to reduce the cases of hypersensitivity reactions based on literature review and guidelines. The Package Leaflet is updated accordingly."

**Piqray - alpelisib -
EMA/H/C/004804/II/0012**

Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with CYP3A4 inducers and inhibitors based on study BYL719A2110, a drug-drug interactions study that evaluated the PK of alpelisib when administered alone or with

rifampin, a strong CYP3A4 inducer, in healthy participants.”

Piqray - alpelisib -

EMA/H/C/004804/II/0013

Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, “Update of the SmPC sections 4.6 and 5.3 in order to add fertility data based on studies 2070119 “BYL719: Oral (Gavage) Study of Fertility in the Male Rat” and 2070120 “BYL719: Oral (Gavage) Study of Fertility and Early Embryonic Development in the Female Rat”.”

Regkirona - regdanvimab -

EMA/H/C/005854/II/0005

Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update the description of Phase 3 of study CT-P59 3.2 following finalisation of the clinical study report from study CT-P59 3.2 Part 2.”

REKAMBYS - rilpivirine -

EMA/H/C/005060/II/0012

Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, “Update of section 4.2 of the SmPC in order to expand oral bridging options for missed planned injections of cabotegravir and rilpivirine based on studies 201584 (FLAIR), 207966 (ATLAS-2M), 200056 (LATTE 2) and 201585 (ATLAS). The Package Leaflet is updated accordingly. In addition, the MAH is taking this opportunity to introduce editorial changes.”

Spikevax - elasomeran -

EMA/H/C/005791/II/0066

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.5 and 5.1 of the SmPC in order to introduce new clinical data regarding the co-administration of Spikevax with a high-dose quadrivalent influenza vaccine (QIV-HD), based on final results from study QHD00028 (NCT04969276), a Phase II, Open-label Study to ‘Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously

Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine’.”

**Vaxchora - cholera vaccine, oral, live -
EMA/H/C/003876/II/0013**

Emergent Netherlands B.V., Rapporteur: Ingrid Wang, “Type II - C.I.4, to update section 6.6 of the SmPC to add the use of carbonated bottled water to reconstitute the vaccine in addition to non-carbonated bottled water. The package leaflet and labelling are updated accordingly. The applicant took the opportunity to submit a corrected Annex A in all languages, which currently presents an inconsistency in the way the strength was stated at MAA approval (as detailed in SmPC).”

**Vocabria - cabotegravir -
EMA/H/C/004976/II/0012**

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, “Update of section 4.2 of the SmPC to introduce an alternative oral therapy for bridging between planned missed injections of cabotegravir and rilpivirine (monthly and every 2 months), based on a retrospective safety analysis of pooled data from 29 subjects in 3 clinical studies (Phase III Studies: 201584, 207966, and 200056). In addition, the Package Leaflet is updated accordingly.”

**Xevudy - sotrovimab -
EMA/H/C/005676/II/0005**

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, “Update of sections 4.4 and 5.1 of the SmPC based on final results from study PC-7831-0157. This is a pharmacology study to determine the neutralisation activity of sotrovimab against SARS-CoV-2 pseudotyped virus expressing the Omicron BA.2.12.1, Omicron BA.4, or Omicron BA.5 spike proteins.”

WS2259

DuoPlavin-

EMA/H/C/001143/WS2259/0063

Iscover-

EMA/H/C/000175/WS2259/0149

Plavix-EMA/H/C/000174/WS2259/0147

sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, “Update of section 4.4 of the SmPC in order to update an existing warning on ‘Bleeding and haematological disorders’ by adding a

statement on triple antiplatelet therapy (clopidogrel + aspirin + dipyridamole) for stroke secondary prevention. The Package Leaflet is updated accordingly.”

B.6.10. CHMP-PRAC assessed procedures

Lamzede - velmanase alfa -

EMA/H/C/003922/II/0027, Orphan

Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser, “Update of section 4.2 the SmPC in order to include the home infusion statement, following the assessment of PSUSA/00010677/202009, based on results from LAMAN-07, Sparkle and Italian Patient Support Program (PSP).

The Package Leaflet and Annex II are updated accordingly. The RMP version 9.1 has also been submitted.”

Lorviqua - lorlatinib -

EMA/H/C/004646/II/0022

Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Nikica Mirošević Skvrce, “Submission of an updated RMP version 5.0 to revise plans for conduct of hepatic impairment studies.

The RMP is updated to reflect the hepatic impairment study B7461009 “A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients” termination and to include new hepatic impairment study B7461040 “A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate The Plasma Pharmacokinetics and Safety of Lorlatinib in Participants with Moderate and Severe Hepatic Impairment Relative to Participants with Normal Hepatic Function”.”

Natpar - parathyroid hormone -

EMA/H/C/003861/II/0042, Orphan

Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, “Submission of the updated protocol from study SHP634-403 listed as a Specific Obligation in the Annex II of the Product Information with twice-daily (BID) as the proposed alternative dosing regimen to be evaluated. This is a Randomized, 2-Arm,

Double-Blind, Phase 4 Study to Evaluate Once Daily (QD) Versus Twice Daily (BID) Administration of Recombinant Human Parathyroid Hormone (rhPTH[1-84]; NATPARA) for the Treatment of Adults with Hypoparathyroidism (HPT).
The Annex II and the RMP (submitted version 3.4) are updated accordingly.”

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from *Spodoptera frugiperda* - EMEA/H/C/005808/II/0014

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a 0.5 mL third dose for Nuvaxovid, to boost subjects that have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an authorised mRNA or adenoviral vector vaccine (heterologous booster dose), based on interim data from study 2019nCoV-101 (Part 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), final data from study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and data from the COV-BOOST study (Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial); the Package Leaflet is updated accordingly. The RMP version 1.2 has also been submitted. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information.”

Vyndaqel - tafamidis -**EMA/H/C/002294/II/0081, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 5.1 of the SmPC in order to update information based on final results from study B3461029 listed as a Specific Obligation in the Annex II of the Product Information. This is a non-interventional PASS sub-study evaluating effects of tafamidis on disease progression in patients with non-Val30Met mutations and symptomatic neuropathy. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

B.6.11. PRAC assessed procedures**B.6.12. CHMP-CAT assessed procedures**

**Breyanzi - lisocabtagene maraleucel /
lisocabtagene maraleucel -****EMA/H/C/004731/II/0002, ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Concetta Quintarelli, CHMP Coordinator:
Armando Genazzani

**Breyanzi - lisocabtagene maraleucel /
lisocabtagene maraleucel -****EMA/H/C/004731/II/0003, ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Concetta Quintarelli, CHMP Coordinator:
Armando Genazzani

Imlygic - talimogene laherparepvec -**EMA/H/C/002771/II/0053, ATMP**

Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuori

Kymriah - tisagenlecleucel -**EMA/H/C/004090/II/0058, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekshus, CHMP Coordinator: Ingrid Wang

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0059, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang,
"Update of section 5.1 of the SmPC based on a subgroup analysis from CCTL019B2401 (B2401) disease registry listed as a PAES (ANX006) in the Annex II; this is a non-interventional study to evaluate the efficacy and safety of Kymriah in ALL patients below the age of 3 years.
In addition, the MAH took the opportunity to update Annex II.D of the SmPC to reflect the fulfilment of the PAES. "

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0061/G, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang

**Zolgensma - onasemnogene abeparvovec -
EMA/H/C/004750/II/0028/G, Orphan,
ATMP**

Novartis Gene Therapies EU Limited,
Rapporteur: Carla Herberts, CHMP Coordinator:
Johann Lodewijk Hillege

B.6.13. CHMP-PRAC-CAT assessed procedures

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0060, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski,
"Update of section 4.2 of the SmPC in order to update the paediatric statement for the B-cell ALL indication and section 4.4 to update the warning on 'prior treatment with anti-CD19 therapy' as well as sections 4.4 and 4.8 in order to update safety data to reflect the pool of the 3 studies B2202, B2205J and B2001X. The proposed changes are in line with the request of the CHMP following the assessment of P46/012. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct the Complete Response Rate (CRR) 95% Confidence Interval (CI) on Enrolled set for E2202 study presented in Table 8 in section 5.1 of the SmPC. The RMP version 5.0 has also been

submitted.”

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2246

Tivicay-EMA/H/C/002753/WS2246/0080

Triumeq-

EMA/H/C/002754/WS2246/0105

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson

WS2255

Juluca-EMA/H/C/004427/WS2255/0043

Tivicay-EMA/H/C/002753/WS2255/0078

Triumeq-

EMA/H/C/002754/WS2255/0103

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson

WS2271/G

Erelzi-

EMA/H/C/004192/WS2271/0041/G

Rixathon-

EMA/H/C/003903/WS2271/0058/G

Riximyo-

EMA/H/C/004729/WS2271/0059/G

Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2282

Hexacima-

EMA/H/C/002702/WS2282/0132

Hexyon-

EMA/H/C/002796/WS2282/0136

Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

WS2284

Edistride-

EMA/H/C/004161/WS2284/0054

Forxiga-

EMA/H/C/002322/WS2284/0075

AstraZeneca AB, Lead Rapporteur: Kristina Dunder, “To reflect the compliance with the agreed completed paediatric investigation plan PIP/0086/20202 as adopted by PDCO in November 2021.”

WS2290

Prezista-
EMA/H/C/000707/WS2290/0117
Rezolsta-
EMA/H/C/002819/WS2290/0048
Symtuza-
EMA/H/C/004391/WS2290/0044

Janssen-Cilag International N.V., Lead
Rapporteur: Johann Lodewijk Hillege

WS2292
Abseamed-
EMA/H/C/000727/WS2292/0099
Binocrit-
EMA/H/C/000725/WS2292/0098
Epoetin alfa Hexal-
EMA/H/C/000726/WS2292/0098
Sandoz GmbH, Lead Rapporteur: Alexandre
Moreau

WS2293
Lyrica-EMA/H/C/000546/WS2293/0119
Pregabalin Pfizer-
EMA/H/C/003880/WS2293/0048
Upjohn EESV, Lead Rapporteur: Johann
Lodewijk Hillege, "To update sections 4.4 and
4.8 of the SmPC and sections 2, 3 and 4 of the
PL, to implement the wording related to the
cases of abuse and dependence in patients
without a history of substance disorder,
following procedures
EMA/H/C/000546/LEG/057 and
EMA/H/C/003880/LEG/009, resulting from
EMA/H/C/PSUSA/00002511/202101."

WS2295
Ongentys-
EMA/H/C/002790/WS2295/0048
Ontilyv-EMA/H/C/005782/WS2295/0002
Bial - Portela & C^a, S.A., Lead Rapporteur:
Martina Weise

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 20-23 June 2022 CHMP plenary:

<i>Oncology</i>	
Treatment of metastatic melanoma ATMP	The CAT and the CHMP denied eligibility to PRIME and adopted the critical summary report.
BNT211 Treatment of testicular germ cell tumours ATMP	The CAT and the CHMP granted eligibility to PRIME and adopted the critical summary report.
Treatment of relapsed/refractory large B cell lymphoma ATMP	The CAT and the CHMP denied eligibility to PRIME and adopted the critical summary report.
<i>Endocrinology-Gynaecology-Fertility-Metabolism</i>	
Treatment of classical homocystinuria in paediatric and adult patients	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Treatment of type 1 diabetes (T1D) mellitus with impaired hypoglycemia awareness and severe hypoglycemia	The PRIME eligibility request has been withdrawn.
<i>Immunology-rheumatology-transplantation</i>	
Prevention of graft rejection following solid organ transplantation (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
<i>Infectious Diseases</i>	
MVA-BN-RSV Active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults ≥60 years of age	The CHMP granted eligibility to PRIME and adopted the critical summary report.
<i>Ophthalmology</i>	
ADVM-022 Treatment of neovascular(wet) age-related macular degeneration (SME) ATMP	The CAT and the CHMP granted eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in June 2022 for July 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address